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ABSTRACT 
_______________________________________________________________________ 
THIMEROSAL-INDUCED NEUROTOXICITY:  APOPTOSIS 
OCCURS THROUGH A MITOCHONDRIAL-MEDIATED PATHWAY 
VIA THE JNK SIGNALING PATHWAY 
by Michelle L. Herdman 
Thimerosal is an organic mercurial containing an ethylmercury moiety attached to the 
sulfur atom of thiosalicylate.  Since the 1930s, thimerosal has been used as an 
antiseptic and a preservative in a wide variety of products, including medicinal 
preparations administered to children and pregnant women.  Past exposures to 
mercurials have indicated that mercury is a neurotoxin, and can also affect the kidney, 
skin, eyes, and immune system.  Additionally, fetuses exposed to mercurials are more 
susceptible to toxicity because the nervous system is continuously developing.  
However, despite its widespread use, thimerosal was only studied on a limited basis until 
the end of the 1990s.  At that time, the use of thimerosal in vaccines began to concern 
parents and physicians because of its potential neurotoxicity, creating a controversy 
surrounding the question of safety.  Consequently, studies with cell culture and animal 
models have begun to discern the mechanisms of toxicity of thimerosal.  The present 
study hypothesized that thimerosal-induced toxicity occurs through the cJun N-terminal 
kinase (JNK)/Activator Protein-1 (AP-1) pathway.  We used a human neuroblastoma cell 
line (SK-N-SH) as a model for neurotoxicity because it has characteristics that resemble 
the developing nervous system.  SK-N-SH cells treated with thimerosal underwent 
apoptosis in a mitochondrial-dependent manner, as demonstrated by release of 
cytochrome c, activation of caspases 9 and 3, degradation of poly(ADP)-ribose 
polymerase (PARP), DNA condensation and fragmentation, along with release of lactate 
dehydrogenase (LDH), which occurs late in apoptosis.  Thimerosal-treated cells also 
showed activation of the JNK pathway through increases in phosphorylation of JNK and 
cJun.  However, despite increases in AP-1 transcriptional activity, use of a dominant 
negative to cJun (TAM67) showed that AP-1 activation is not essential to thimerosal-
induced apoptosis.  Use of a cell permeable JNK inhibitor (SP600125) demonstrated 
that JNK activation is a necessary component of thimerosal-induced apoptosis.  An 
additional component of thimerosal toxicity is an increase in oxidative stress.  
Antioxidants were used to determine if the oxidative stress component was connected to 
the JNK pathway activation.  The antioxidant Trolox and the glutathione precursor N-
acetylcysteine (NAC) both protected the cells from apoptosis, but served to increase the 
phosphorylation of JNK, while still decreasing levels of the proapoptotic protein Bim.  
Additionally, the JNK inhibitor decreased levels of the stress-response protein heme 
oxygenase-1 (HO-1).  These results indicate that while the oxidative stress pathway and 
the JNK pathway may be affected by the actions of the other, additional intermediates 
are involved.   Taken together, these results present a significant increase in the 
cumulative information concerning the mechanism of thimerosal-induced neurotoxicity.  
By increasing the overall knowledge base, we provide targets for the development of 
methods to attenuate potential neurotoxicity in patients exposed to thimerosal. 
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CHAPTER I 
 
Introduction 
 
1.1 Thimerosal and Neurotoxicity 
 
Thimerosal (sodium ethylmercury thiosalicylate, thiomersal, merthiolate) is 
an organic mercurial, containing an ethylmercury moiety attached to the sulfur 
atom of thiosalicylate.  Since the 1930s, thimerosal has been used in many 
products as an antiseptic and a preservative.  In recent years, controversy has 
surrounded the use of thimerosal in vaccines, as mercury is a known neurotoxin 
and nephrotoxin, and can affect other areas of the body as well.  Parents began 
to be concerned about the possibility that thimerosal could be causing 
neurological disorders, particularly autism, because symptoms of autism often 
appeared following a round of routine vaccinations.  This concern spurred a 
movement among parents, as well as some physicians, to stop vaccinating 
children, creating a risk of children acquiring deadly illnesses.  The Institutes of 
Medicine (IOM), Food and Drug Admnistration (FDA), and Centers for Disease 
Control and Prevention (CDC) began to investigate the possibility that thimerosal 
was connected to these neurological disorders.  In 2001, IOM and FDA issued a 
statement that not enough evidence existed to confirm that thimerosal did or did 
not cause these disorders, but the possibility did exist.  As a result, it was 
recommended that thimerosal be removed from vaccines administered to 
children.  Since the controversy began in the late 1990s, much of the thimerosal 
has been removed from vaccines administered in the United States.  However, it 
remains in some, such as the influenza vaccine, and is added to multidose vials 
used in countries around the world.  In a subsequent report issued in May 2004, 
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IOM stated that there is no connection between thimerosal and autism.  
However, many parents, physicians, and scientists still believe that a connection 
exists between neurodevelopmental disorders and thimerosal.  Ongoing studies 
will provide valuable information on how this mercurial can affect the brain.   
Studies concentrating on thimerosal-induced neurotoxicity are limited, and 
exposure guidelines, such as those set by the FDA and Environmental Protection 
Agency (EPA), are based on methylmercury studies, which are abundant.  
Interestingly, some studies suggest that ethylmercury may react differently than 
methylmercury.  The current toxicological profile of thimerosal is limited in all 
respects, not just concerning its neurotoxic properties.  However, with recent 
concern about the administration of thimerosal-containing medicinal products to 
populations that are vulnerable to neurotoxicity, more studies are necessary to 
establish molecular events occurring following thimerosal exposure.  In particular, 
signaling pathways affected by thimerosal present targets for development of 
pharmacological agents that could attenuate toxic effects in patients exposed to 
products containing this preservative.  
 
1.2 Hypothesis 
 
It is hypothesized that thimerosal-induced neurotoxicity occurs through a 
cJun N-terminal kinase (JNK)/Activator protein-1 (AP-1)-mediated pathway. 
 
1.3 Selection of Neurotoxicity Model 
 
The human SK-N-SH neuroblastoma cell line was chosen as the model for 
studying thimerosal-induced neurotoxicity.  Neuroblastoma cell lines are routinely 
used as models for studying neurotoxicity.  The SK-N-SH cell line is a mixed cell 
line of neuroblasts and epithelial cells.  This cell line represents the 
undifferentiated characteristics of an immature nervous system as would be 
3 
found in the fetus, neonate, and infant, as opposed to the terminally differentiated 
state found in the adult brain. 
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CHAPTER II 
 
Review of Literature 
 
2.1 Mercury 
 
2.1.1 Mercury Exposure 
 
Mercury is both a naturally occurring element and a bi-product of human 
activities, particularly industrial emissions, medical uses, and improper disposal 
of mercury-containing products.  Human exposure to mercury occurs through 
three main forms: elemental mercury, inorganic mercury, and organic mercurials.  
Elemental mercury includes both the liquid and the vapor forms.  Naturally 
occurring elemental mercury can be found in cinnabar ore and can be released 
as a gas during volcanic eruptions, while elemental mercury from human 
endeavors has numerous sources, including thermometers, barometers, dental 
amalgams, and in emissions from coal-burning power plants and medical waste 
incinerators.  Exposure can occur through direct contact or inhalation of mercury 
vapor.  Inorganic mercury salts are present in products used by both adults and 
children, including skin-lightening creams and germicidal soaps (Counter and 
Buchanan, 2004).  Finally, organic mercurials include methylmercury, 
ethylmercury, and phenylmercury.  The most common exposure to 
methylmercury occurs through the ingestion of contaminated fish.  Exposure to 
ethylmercury can occur in the occupational setting and through the use of 
medicinal preparations containing thimerosal (Clarkson, 2002).  Similarly, 
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exposure to phenylmercury can occur through the use of medicines, such as 
nasal sprays and ophthalmic ointments, containing this compound or through 
occupational exposures (http://www.fda.gov/cder/fdama/mercury300.htm).   
 
2.1.2 Mercury Toxicity 
 
Key pieces of information concerning the mechanism of mercury toxicity 
have been derived both from cases of patient exposure and from experimental 
studies.  Symptoms of exposure to each type of mercury have given clues to the 
primary targets of toxicity, and experimental studies have confirmed that one of 
the primary targets is the brain, along with the kidneys, lungs, skin, eyes, and 
immune system.  Patients exposed to mercury vapor can experience symptoms 
of acute toxicity, which include flu-like symptoms, pulmonary damage, stomatitis, 
confusion, lethargy, and vomiting.  Acute toxicity has been reported to lead to 
fatal acute respiratory distress syndrome (Diner and Brenner, 2004).  Lower 
levels of exposure over time can lead to chronic toxicity, which can manifest as 
tremors, changes in behavior and mood, and damage to kidneys (Clarkson, 
2002).  However, both acute and chronic exposure can lead to a variety of other 
symptoms, including edema in the hands and feet, shortness of breath, gingivitis, 
hallucinations, and the syndrome known as erethism, which consists of 
excitability, insomnia, shyness, and loss of memory (Counter and Buchanan, 
2004), as well as depression, anorexia, and uncontrolled perspiration (Diner and 
Brenner, 2004).  Symptoms for exposure to inorganic mercury compounds are 
similar to symptoms described for exposure to other forms, and can also include 
weakness in extremities, redness of the skin, rash, excessive salivation, and 
neuropsychiatric disorders (Counter and Buchanan, 2004).  Methylmercury 
exposures can also lead to a wide variety of symptoms.  These can include many 
of those mentioned above, as well as paresthesia of the mouth, hands, and feet, 
which may be due to damage to either the central or peripheral nervous system, 
muscle incoordination, constriction of the visual field and deafness (Clarkson et 
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al., 2003; Sanfeliu et al., 2003).  In the case of methylmercury toxicity, symptoms 
appear following a latent period of a few to several weeks after exposure 
(Clarkson et al., 2003).  Most studies using phenylmercury compounds are based 
on its chemical properties and only a few address its toxicity, so those studies will 
not be discussed here.  As mentioned above, ethylmercury exposure occurs 
primarily with thimerosal, which will be addressed in detail in the following 
section.   
 Studies to determine the mechanism of mercury toxicity have focused on 
both the targets and the molecular events following exposure to the various 
mercurials.  In workers exposed to the vapor form in the occupational setting, 
autopsy samples found that mercury is localized mainly in the brain, kidney, and 
lung, with other areas also showing storage, including the testes, thyroid, and 
liver (Barregard et al., 1999; Opitz et al., 1996).  Studies looking at deposition of 
other forms of mercury have found similar distribution, with the primary targets 
being the brain and kidney (Friberg and Mottet, 1989; Magos, 2001; Clarkson, 
2002; Clarkson et al., 2003; Counter and Buchanan, 2004; Diner and Brenner, 
2004).  Additionally, studies have indicated that mercurials can cause activation 
of the immune system, primarily through hypersensitivity reactions and 
autoimmune disorders, and can also cause immunosuppression (Koller, 1973; 
Pollard and Hultman, 1997; Moszczynski, 1997; Fournie et al., 2002; Nielsen and 
Hultman, 2002; Hansson et al., 2005; Haggqvist et al., 2005; Havarinasab and 
Hultman, 2005).   
In order to determine the mechanism of damage caused by mercurials, 
numerous studies have investigated the molecular events occurring following 
exposure to the various types of mercury-containing compounds to which 
humans could be exposed.  Studies with mercuric chloride indicate that in a 
human leukemic cell line apoptosis occurs through a mitochondrial-dependent 
mechanism, including cytochrome c release, caspase 3 activation and 
degradation of poly(ADP)-ribose polymerase (PARP; Araragi et al., 2003).  Guo 
et al. (1998) found that mercuric chloride can also induce apoptosis in human T 
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lymphocytes through production of reactive oxygen species (ROS) and disruption 
of mitochondrial function without release of cytochrome c.  Additionally, studies 
show that inorganic mercury can selectively inhibit one apoptotic pathway (CD95-
induced apoptosis), while not affecting another (TNF-α-induced apoptosis; 
McCabe, Jr et al., 2005).  Ben-Ozer et al. (2000) demonstrated that low levels of 
mercuric chloride damaged DNA without causing apoptosis in a human cell line 
with characteristics of monocytes.  The apoptotic response in these models 
indicates a possible mechanism for suppression of the immune system following 
mercury exposure, while the selectivity of some of the responses leaves open the 
possibility of subsequent immune activation.  Studies comparing cell death in 
human mononuclear cells treated with either methylmercury chloride (MeHgCl) or 
mercuric chloride (HgCl2) found that while both mercurial species induced 
apoptosis, each affected the cells in a different way.  Both species affected 
mitochondrial function, but HgCl2 did not cause release of cytochrome c and 
caused an increase in anti-apoptotic Bcl-2.  On the contrary, MeHgCl did cause 
release of cytochrome c and no increase in Bcl-2.  Additionally, both forms of 
mercury were able to activate the caspase cascade, as seen by cleavage of the 
caspase 3 substrate PARP (Shenker et al., 2000).  In studies with cultured rat 
astrocytes, Brawer et al. (1998) found that mercuric chloride can increase ROS 
and can induce a stress response in these cells, including an increase in mRNA 
levels of heme oxygenase-1 (HO-1).   
 Numerous studies have been conducted with methylmercury since it is 
one of the greatest exposure risks to humans.  Because one of the primary 
concerns is neurotoxicity following methylmercury exposure, many studies have 
focused on damage to the brain and the mechanism of that toxicity.  One of the 
main concerns with methylmercury exposure is the risk to the developing fetus.  
Methylmercury can cross both the placenta and the blood-brain barrier (Mansour 
et al., 1973,1974; Aschner and Aschner, 1990; Kakita et al., 2000), allowing for 
significant damage to the developing fetus, leading to motor, sensory, and mental 
impairment, as well as neuropsychological disorders (Clarkson, 2002; Clarkson 
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et al., 2003; Sanfeliu et al., 2003; Counter and Buchanan, 2004).  Additionally, 
studies have reported that methylmercury, as well as ethylmercury, can undergo 
biotransformation to inorganic mercury once inside cells, possibly causing further 
damage (Norseth and Clarkson, 1970; Vahter et al., 1994; Blair et al., 1975; 
Suda et al., 1992), although the contribution of the inorganic mercury to 
subsequent damage has yet to be determined.   
 Further studies examining the mechanism of methylmercury-induced 
toxicity have involved determining the molecular events following exposure.  
Again, as with other reports, many of these studies have concentrated on 
damage to immune system components and to the brain.  Shenker et al. (1998, 
1999, 2000) found that methylmercury causes a decline in mitochondrial function, 
subsequent generation of ROS, and, ultimately, apoptosis in human T-cells.  
Many other studies have implicated the production of ROS in cellular damage 
following methylmercury exposure, many of which demonstrate the protective 
effect of antioxidants (Ali et al., 1992; Sarafian et al., 1994; Choi et al., 1996; 
Sorg et al., 1998; Sanfeliu et al., 2001).  Cerebellar neurons, a main target for 
mercurials, also underwent apoptosis following methylmercury treatment 
(Kunimoto, 1994; Nagashima et al., 1996).  Allen et al. (2001) demonstrated that 
methylmercury selectively targets the mitochondria of cultured astrocytes, 
another target for mercurials.  Additional studies with HeLa cells have 
demonstrated that both methylmercury and ethylmercury inhibit DNA and RNA 
synthesis (Chao et al., 1984), which could be another mechanism by which 
mercurials induce cellular damage and death.  Methylmercury has also been 
shown to block microtubule polymerization, which causes a significant effect on 
cell division and migration during development (Sanfeliu et al., 2003).  Taken 
together, these studies indicate that mercurials may act through a variety of 
pathways, including increasing ROS, activating apoptosis-inducing signaling 
pathways and causing direct injury to cellular components, to cause cell damage 
and death.   
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2.2 Thimerosal 
 
2.2.1 Background 
Thimerosal, also known as thiomersal, merthiolate, or sodium 
ethylmercurithiosalicylate, consists of an ethylmercury moiety attached to the 
sulfur atom of thiosalicylate (Figure 2.1).  The sulfur-mercury attachment point is 
the reactive site of the molecule, allowing for reactions with sulfhydryl groups of 
cellular components, including glutathione, enzymes, and structural proteins.  
Thimerosal is both water-soluble and lipophilic, able to cross cellular membranes 
as a free acid (Elferink, 1999).   
 
2.2.2 Usage 
            Thimerosal has antifungal and antibacterial properties and has been used 
extensively as an antiseptic and a preservative since the 1930s.  Thimerosal is still 
used in a variety of medicinal products, including nasal sprays, antibiotic eye and 
ear drops, antifungal creams/lotions, and a multitude of ophthalmic solutions 
(http://www.fda.gov/cder/fdama/mercury300.htm).  Most notably, thimerosal is 
used in numerous vaccines available in the United States (Table 1; 
http://www.fda.gov/cber/vaccine/thimerosal.htm), as well as in vaccines and other 
medicinal products used around the world.  In the late 1990s, controversy began to 
surround this usage, particularly in vaccines and other medicinal products that 
were administered to neonates, infants, children, and pregnant women.  Several 
vaccines have been added to the childhood vaccination schedule, and in some 
cases the cumulative dose of mercury a child received was exceeding the daily 
amount allowed by EPA guidelines (0.1 μg/kg/day; Ball et al., 2001; Clements et 
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al., 2001).   Subsequently, thimerosal has been removed from most pediatric 
vaccines in the United States, with the exception being the influenza vaccine  
Figure 2.1.  Structure of thimerosal. Thimerosal
consists of ethylmercury attached to the sulfur atom 
of thiosalicylate.  This sulfur-mercury attachment 
point is also the reactive sight of the molecule.  
Thiosalicylate Ethylmercury
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THIMEROSAL-CONTAINING VACCINES 
AVAILABLE IN THE UNITED STATES 
 
Vaccine (Tradename) Thimerosal Content 
DTaP (Tripedia) ≤ 0.3 μg Hg/0.5 mL dose 
DTaP-HepB-IPV (Pediarix) <0.0125 μg Hg/0.5 mL dose 
DT (No trade name)-single dose <0.3 μg Hg/0.5 mL dose 
DT (No trade name)-multidose 0.01% (25 μg Hg/0.5 mL dose) 
Hepatitis B (Engerix B) < 0.5 μg Hg/0.5 mL dose 
Hepatitis B (Recombivax HB)-adult 25 μg Hg/0.5 mL dose 
Hep A/Hep B (Twinrix) < 1 μg Hg/1.0 mL dose) 
Influenza (Fluzone) 0.01% (12.5 μg Hg/0.25 mL dose) 0.01% (25 μg Hg/0.5 mL dose) 
Influenza (Fluzone Preservative Free) ≤ 0.5 μg Hg/0.25 mL dose ≤ 1.0 μg Hg/0.5 mL dose 
Influenza (Fluvirin) 0.01% (25 μg Hg/0.5 mL dose) 
Influenza (Fluvirin Preservative Free) <1.0 μg Hg/0.5 mL dose 
Japanese Encephalitis (JE-VAX) 35 μg Hg/1.0 mL dose 17.5 μg Hg/0.5 mL dose) 
Meningicoccal (Menomune A, C, AC 
and A/C/Y/W-135-mulitdose 0.01% (25 μg Hg/0.5 mL dose) 
Td (No trade name) 8.3 μg Hg/0.5 mL dose 
Td (Decavec) 0.3 μg Hg/0.5 mL dose 
TT (No trade name) 0.01% (25 μg Hg/0.5 mL dose) 
 
Table 1.  Thimerosal-containing vaccines.  Many vaccines still contain 
thimerosal.  However, thimerosal-free options are available for children.  DtaP= 
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine; DT= Diphtheria & 
Tetanus Toxoids; HepB=Hepatitis B; IPV= Inactivated Poliovirus Vaccine; 
HepA=Hepatitis A; Td= Tetanus & Diphtheria Toxoids; TT= Tetanus Toxoid. 
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(Table 1), which is recommended for children ages 6 months and older, as well as 
pregnant women.  Furthermore, medicinal products used in developing nations still 
contain thimerosal and are given to children of all ages, as well as pregnant 
women (Clements et al., 2001).     
2.2.3 Symptoms of Toxicity 
            Symptoms of ethylmercury toxicity have been established through cases of 
patient exposures from occupational, dietary, and medicinal sources.  According to 
Magos (2001) blood mercury levels approaching or exceeding 1 μg/mL 
corresponded with symptoms of toxicity, with levels above 15 μg/mL of mercury 
resulting in several fatal cases.  In these cases of toxicity, symptoms did not occur 
until weeks after exposure.  One of the most common symptoms of ethylmercury 
toxicity was constriction of the visual field.  Patient symptoms varied, and included, 
but were not limited to, symptoms similar to mercury vapor exposure, with 
additional symptoms of paresthesia, which may be due to lesions of the central or 
peripheral nervous system, hypoesthesia, disturbance of speech, hearing loss, 
incoordinate muscle activity, muscle weakness and spasticity, tremor, confusion, 
and delirium.  In cases of injection of large amounts of thimerosal, necrosis 
occurred at the injection site (Magos, 2001). 
            An additional problem with thimerosal, as with other mercurials, is the effect 
on the immune system.  Allergic contact dermatitis is a common reaction following 
exposure to thimerosal, with most cases involving a localized reaction.  However, 
Lee-Wong et al. (2005) present a case study of a patient that developed systemic 
contact dermatitis.  Following sensitization with thimerosal-containing contact lens 
solution, the patient developed a T-cell-mediated reaction after receiving an 
influenza vaccine, leading to a maculopapular rash on all four extremities and the 
torso.   
2.2.4 Toxicity Studies-Cell Culture 
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As with other mercurials, thimerosal appears to elicit effects on a variety of 
cells types, thus accounting for the toxic symptoms observed in a variety of organ 
systems.  One of the effects of thimerosal that has been studied most extensively 
is calcium alterations.  Thimerosal caused increases in intracellular calcium in rat 
thymus lymphocytes, and these changes were dependent on the influx of 
extracellular calcium (Martin et al., 1991).  Thimerosal also caused similar 
changes in human umbilical cord vein endothelial cells by increasing the influx of 
extracellular calcium and by releasing intracellular stores.  This study indicates a 
possible mechanism by which thimerosal increases levels of nitric oxide and 
prostacyclin, and thus cause vasodilation (Gericke et al., 1993).  Similar changes 
in intracellular calcium caused by the synergistic effects of thimerosal and N-
formyl-methionyl-leucyl-phenylalanine led to the increased formation of 
leukotrienes following the liberation of arachidonic acid in human 
polymorphonuclear white blood cells (Hatzelmann et al., 1990).  Rat cerebellar 
neurons treated with thimerosal also showed increases in intracellular calcium 
levels (Ueha-Ishibashi et al., 2004a).  Changes in calcium levels can lead to a 
variety of outcomes, including apoptosis, and could be a possible mechanism 
through which thimerosal causes damage to cells.  Chao et al. (1984) 
demonstrated that ethylmercuric chloride inhibited both DNA and RNA synthesis 
in HeLa cells, which could also lead to apoptosis.   
Another event associated with cellular damage is an increase in reactive 
oxygen species.  HeLa S cells treated with thimerosal showed activation of focal 
adhesion kinase and cytoskeletal changes, both of which were attributed to the 
production of ROS (Kim et al., 2002).  Furthermore, decreased glutathione levels 
were seen in rat cerebellar neurons (Ueha-Ishibashi et al., 2005), rat thymocytes 
(Ueha-Ishibashi et al., 2004b), Jurkat T cells (Makani et al., 2002), cultured 
neuroblastoma cells (SH-SY5Y) and glioblastoma cells (James et al., 2005).  An 
increase in ROS and subsequent decrease and possible depletion of glutathione 
could lead to cellular damage and apoptosis, as was shown by Makani et al., 
(2002).  Debbasch et al. (2001) also found an increase in ROS in a human 
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conjunctival cell line treated with thimerosal.  Baskin et al. (2003) found evidence 
that cultured human neurons and fibroblasts undergo apoptosis following 
thimerosal treatment.  Researchers demonstrated that thimerosal exposure at 
micromolar concentrations led to membrane damage, along with apoptotic cell 
death as shown by DNA condensation and fragmentation, caspase 3 activation, 
and the presence of apoptotic bodies.  Micromolar concentrations of thimerosal 
also caused changes in mitochondrial membrane potential, increases in ROS, 
and translocation of pro-apoptotic Bax to the outer mitochondrial membrane, 
while at the same time showing no changes in levels of Bax or Bcl-2 in a 
neuroblastoma cell line (Yel et al., 2005).   
To begin to address the question of the effects of thimerosal on the 
development of the brain, Parran et al. (2005) used SHSY5Y neuroblastoma 
cells to determine if thimerosal exposure affected nerve growth factor (NGF) 
signaling.  They found that neuroblastoma cells exposed to thimerosal and NGF 
showed decreased phosphorylation, and thus decreased activation, of the NGF 
receptor and mitogen-activated protein kinases (MAPK), indicating that 
neurotropin signaling may be a target for thimerosal in the developing brain.  
SHSY5Y cells treated with thimerosal had decreased methionine synthase 
activity and corresponding blocks in stimulatory effects of dopamine and insulin-
like growth factor-1 (IGF-1).  These results indicate that thimerosal may interfere 
with D4 dopamine receptor-mediated phospholipid methylation as well as DNA 
methylation, which has been linked to attention deficit disorder (Waly et al., 
2004).  In the first study to identify that thimerosal also caused mitochondrial-
mediated apoptosis, our lab showed the release of cytochrome c, activation of 
caspases 9 and 3, and degradation of PARP in SK-N-SH neuroblastoma cells 
(Humphrey et al., 2005).   
 
 
 
15 
2.2.5 Toxicity Studies-Animal Studies 
Studies are limited using animal models to examine the toxic effects of 
thimerosal.  Blair et al. (1975) found that squirrel monkeys that were given high 
doses of thimerosal intranasally for six months showed no signs of toxicity, as 
determined by changes in weight and food consumption, changes in hematologic 
parameters and blood chemistry, as well as organ damage.  However, they 
accumulated significant levels of mercury, mostly in the inorganic form, in the 
brain, liver, kidney, and muscle.  Although the animals showed no signs of 
toxicity, the accumulation of mercury in the brain is of concern to humans, as it 
poses a potential health risk.  Gasset et al. (1975) found similar results in studies 
using albino New Zealand rabbits.  When thimerosal was applied either topically 
to the eye or subcutaneously, mercury was present in the blood, brain, liver, and 
kidney.  Oral thimerosal administration to A.SW mice led to accumulation of both 
ethylmercury and Hg2+ in kidney, liver, and mesenterial lymph nodes 
(Qvarnstrom et al., 2003).  CD1 mice given a single injection of thimerosal 
showed mercury present in the blood, brain, kidney, and muscle tissue, and 
levels in the brain, though not as high as other tissues, remained elevated after 7 
days (Harry et al., 2004).  Results on infant monkeys (Macaca fascicularis) found 
similar results.  Researchers found that infant monkeys that received 
intramuscular injections of thimerosal showed increases in inorganic mercury 
levels in the brain, and the average level did not decrease by 28 days, which 
corresponds to the significantly longer half-life of inorganic mercury (Burbacher et 
al., 2005).  Importantly, studies have indicated that genetic susceptibility may 
play a role in sensitivity to thimerosal-induced toxicity.  Studies comparing 
different mouse strains (SJL/J, C57BL6/J, BALB/cJ) found that the SJL/J 
autoimmune-sensitive strain was more susceptible to toxicity than the other 
strains, indicating that perhaps there is a genetic predisposition to thimerosal 
sensitivity (Hornig et al., 2004).  In studying the immunosuppressive and 
autoimmune effects of thimerosal on a variety of mouse strains, Havarinasab et 
al. (2004, 2005) found similar genetic susceptibility to thimerosal based on major 
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histocompatibility complex (MHC) haplotypes.  Additionally, they found that 
thimerosal causes an initial immunosuppression, but by two weeks, thimerosal 
caused an extensive autoimmune response. 
 
2.2.6 Toxicity Studies-Human 
 
Few toxicity studies have been conducted to look at human exposure to 
thimerosal.  Pichichero et al. (2002) studied infants following administration of 
thimerosal-containing vaccines.  They measured levels of mercury in blood, 
urine, and stool samples 3-28 days after vaccination, and found that blood and 
urine mercury levels were low at the time point measured, but levels were high in 
stools, indicating that the primary route of elimination is through the stools.  
Stajich et al. (2000) measured mercury levels in both term and preterm infants 48 
to 72 hr after receiving one dose thimerosal-containing Hepatitis B vaccine 
(contained 12.5 μg mercury) during the first week of life.  They found that both 
groups of infants had significantly increased post-vaccination blood mercury 
levels, and the preterm infants had higher mean mercury level than the term 
infants.  These higher levels may be due to the relatively higher amount of 
mercury received by the lower birth weight infants, as well as to the possibility 
that the preterm infants may not be able to eliminate the mercury as effectively 
as the term infants.  
 
2.2.7 Comparison of Ethylmercury and Methylmercury 
Organizations that set guidelines for exposure to ethylmercury have based 
the safe levels on studies with methylmercury and have assumed that the two 
forms of mercury have similar toxicities.  Therefore, studies that compare the 
effects of methylmercury and ethylmercury are important and necessary to 
determine if safety guidelines are correctly estimating the relative toxicities of 
both compounds.  Studies using ethylmercuric chloride and methylmercuric 
chloride administered to Porton Wistar rats demonstrated that ethylmercury 
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caused a larger weight loss and greater amounts of total and organic mercury in 
the blood than methylmercury.  Methylmercury caused higher levels of total and 
organic mercury in the brain and kidneys, as well as more severe coordination 
disorders.  However, ethylmercury specifically affected the telencephalon and 
diencephalon, with mercury deposits visible upon staining, while methylmercury 
did not deposit in these areas.  Additionally, ethylmercury caused more 
widespread damage to the kidneys than methylmercury, which showed higher 
levels of mercury deposition.  This discrepancy was attributed to the fact that in 
ethylmercury-exposed kidneys the damage was so significant that large amounts 
of mercury deposits may have been lost as damaged cells were sloughed off.  
Finally, by increasing the ethylmercury dose by 20%, many of these parameters 
increased equal to or above the levels seen in methylmercury.  For instance, the 
increase in ethylmercury caused increased levels of coordination disorders that 
were equal to or higher that methylmercury-treated rats (Magos et al., 1985).   
 Other basic differences have also been discovered.  The half-life of 
methylmercury has been estimated to be about 50 days, while the half-life of 
ethylmercury has been estimated to be only about 7 days (Pichichero et al., 
2002; Counter and Buchanan, 2004).  Methylmercury is actively transported into 
the brain by an amino acid transporter, while thimerosal crosses membranes in 
the free acid form (Elferink, 1999; Counter and Buchanan, 2004), but both have 
been shown to accumulate in the brain and to be converted to inorganic mercury.  
However, ethylmercury is converted to inorganic mercury at a much higher rate 
than methylmercury (Clarkson, 2003).  On the other hand, some similarities have 
also been found.  Both readily bind to sulfhydryl groups, and excretion of both 
forms occurs mainly through the fecal route.  Additionally, both compounds have 
similar distribution patterns in the body.  Finally, following exposure to either 
compound, there is a latent period before symptoms of toxicity appear (Magos, 
2001; Clarkson, 2003; Counter and Buchanan, 2004).  Therefore, despite some 
similarities, methylmercury and ethylmercury exhibit enough differences that they 
should be considered separately when determining the potential for toxicity.   
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2.3 cJun N-Terminal Kinase (JNK)/Activator Protein-1 (AP-1) 
 
2.3.1 Background-JNK 
Mitogen-activated protein kinases (MAPK) play an important regulatory 
role in a variety of cellular processes, including growth, differentiation, cellular 
migration, and apoptotic cell death.  Three groups of MAPKs (p38, JNK, and 
ERK) have been identified in mammals (Figure 2.2), each of which is the terminal 
kinase in a protein kinase cascade (Davis, 2000).  Overall the MAPK cascades 
can be activated by a variety of physical and chemical stimuli, including growth 
factors, cytokines, environmental insults, heat, ROS, and changes in pH and 
osmolarity (Karin and Gallagher, 2005; Sumbayev and Yasinska, 2005).  The 
cJun N-terminal kinase (JNK), also known as stress-activated protein kinase 
(SAPK), is a serine/threonine kinase that is activated by environmental stresses 
and is of particular interest in relation to signaling responses following the 
genotoxic insult of thimerosal.  The JNK family of protein kinases consists of 
three JNK genes, which produce 10 JNK isoforms.  All 10 JNK isoforms are 
either 46 kDa or 54 kDa molecular weight (MW).  JNK1 and JNK2 genes are 
expressed ubiquitously, while JNK3 is expressed mostly in the brain, but also in 
the heart and testis (Kuan et al., 1999; Davis, 2000).   
  
2.3.2 Activation and Inactivation 
The JNK MAPKs are activated by phosphorylation of the Threonine-
Proline-Tyrosine (Thr-Pro-Tyr) motif by an upstream MAPK kinase.  MKK4 and 
MKK7 specifically phosphorylate JNKs.  MKK4 and MKK7 isoforms are activated 
by upstream MAPKK kinases (MAPKKK).  The MAPK kinases (MAPKK) both 
dually phosphorylate JNKs on Thr and Tyr, MKK7 preferentially phosphorylates 
on Thr and MKK4 on Tyr, indicating that while they can work individually, the  
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MAPK Signaling Cascades
Stress, Growth Factors, Cytokines, Mitogens,            
G Protein Coupled Receptors (GPCR)
ERK p38JNK
MEK1/2/5 MKK4/7 MKK3/6
MAPKKK MAPKKKMAPKKK
Apoptosis, Development, 
Differentiation, Growth, 
Inflammation
Figure 2.2.  MAPK Signaling Cascades.  Following exposure to a 
stimulant, any of a variety of MAPKKKs can be activated, depending on 
the stimuli, and can phosphorylate downstream MAPKK, which, in turn, 
phosphorylate MAPK (ERK, JNK, or p38).  The terminal MAPK in the 
cascade can then proceed to phosphorylate other cellular components, 
such as transcription factors, leading to a biological response.
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MAPKKs may also work together to activate JNK.  Additionally, MKK7 and MKK4 
are primarily activated by cytokines and environmental insults, respectively.  Both 
MAPKKs are present in the nucleus and the cytoplasm; therefore, JNKs can be 
activated in both locations.  The MAPKKKs that activate MAPKK upstream of 
JNKs include MEKK1 through 4, ASK1 and 2, TAK1, TPL2, and members of the 
mixed-lineage protein kinase group.  JNK may be activated either transiently or in 
a sustained manner, which could determine the outcome of JNK signaling (Davis, 
2000).  Differential activation of JNK isoforms, as well as activation of upstream 
MKKs, has been shown to depend on both cell type and the particular cellular 
stress (Butterfield et al., 1999; Mielke et al., 2000).  Activation of specific JNK 
genes, as well as activation of specific downstream substrates, was also shown 
to occur in response to growth and differentiation signals (Behrens et al., 1999).  
In addition, scaffolding molecules, such as the JNK-interacting proteins (JIP), 
may potentiate JNK signaling, although the exact mechanism has not been 
elucidated.  Inactivation of JNK protein kinases occurs through 
dephosphorylation by phosphatases (Davis, 2000). 
 
2.3.3 Function 
Activated JNK isoforms can proceed to phosphorylate other cellular 
proteins, including transcription factors.  JNK has been shown to phosphorylate 
c-Jun, activating transcription factor-2 (ATF2), Elk-1, c-Myc, p53, 14-3-3, Bcl-2, 
Smac, and Bim (Brichese et al., 2004; Tsuruta et al., 2004; Karin and Gallagher, 
2005). 
 JNK is activated by cellular stress and may play a role in either apoptosis 
or survival.  JNK has been shown to be essential to apoptosis (Morishima et al., 
2001; Kuan et al., 1999; Tournier et al., 2000), and, more specifically, the JNK3 
gene has been shown to be involved in neuronal apoptosis (Yang et al., 1997).  
The targets for JNK in apoptosis are still being elucidated.  While several 
candidates have emerged, their roles in JNK-induced apoptosis are unclear, and, 
in some cases, these targets do not appear to be essential to the signaling 
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pathway even though they are involved.  This is the case for p53 and c-Myc 
(Davis, 2000).  Studies with murine embryo fibroblasts (MEF) from Jnk1-/- Jnk2-/- 
embryos indicate that JNK activity is required for mitochondrial-mediated, but not 
caspase-8-mediated, apoptosis in response to UV radiation.  JNK was required 
for release of cytochrome c, which combines with Apaf-1, ATP, and procaspase-
9, leading to the activation of caspase-9 and caspase-3 (Tournier et al., 2000; 
Figure 2.3).  However, the exact role of JNK in this pathway is unknown, as all 
intermediates have not been determined.  Similar activation of JNK has been 
established in response to cadmium in neuronal apoptosis, including the 
involvement of cJun and caspase 3 (Kim et al., 2005b).  One mechanism through 
which JNK may be acting is phosphorylation of either proapoptotic or 
antiapoptotic proteins or both.  One such proapoptotic protein that JNK can 
phosphorylate is Bim.  Activation of Bim through phosphorylation allows Bim to 
contribute to apoptosis by interaction with other Bcl-2 proteins (Becker et al., 
2004; Harris and Johnson, 2001; Lei and Davis, 2003; Okuno et al., 2004; 
Putcha et al., 2003).  Under normal conditions, Bim is attached to LC8 in the 
dynein motor complex, but translocates to the mitochondrial membrane when 
activated, wherein Bim interacts with Bax/Bad, causing pore formation and 
cytochrome c release, ultimately leading to apoptosis.  When released from the 
microtubules, Bim can also interact with and neutralize antiapoptotic Bcl-2 
proteins, which also leads to apoptosis (Mollinedo and Gajate, 2003).  According 
to Putcha et al., (2001) this Bim-mediated apoptosis is specific to neuronal cells, 
and does not occur in non-neuronal cells in the brain.  
 Less information is known about the role JNK may play in survival 
signaling.  This role may be related to a transient activation of JNK, as opposed 
to the sustained activation that occurs during apoptosis.  JNK is only transiently 
activated in response to cytokines, and apoptosis does not occur (Davis, 2000).  
Evidence for this hypothesis of JNK survival signaling was found in studies of 
JNK1-/-JNK2-/- embryos that had increased apoptosis in the forebrain, while at the 
same time these embryos had reduced apoptosis in the hindbrain, indicating that 
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JNK-mediated survival and apoptosis signaling may both be essential to brain 
development (Kuan et al., 1999; Sabapathy et al., 1999).  
 JNK may also be involved in tumor development, albeit the exact role is 
still unclear.  One hypothesis is that JNK-induced apoptosis may be inhibited in 
some manner.  Since JNK1 and JNK2 are ubiquitously expressed, this inhibition 
may occur through either proteins that directly inhibit JNK activation or through 
inhibition of proteins that activate JNK.  Targets of JNK pro-apoptotic signaling 
may also be altered and can no longer respond as they would in normal cells 
(Davis, 2000). 
 JNK also functions in embryonic development, but many more studies will 
be necessary to determine its exact role.  Studies using embryos possessing 
JNK gene mutations have demonstrated that the complement of JNK genes are 
essential to embryonic viability, and JNK survival and apoptotic signaling appear 
to be necessary for normal embryonic development (Kuan et al., 1999).    
 
2.3.4 Background-AP-1 
Many biological responses attributed to the JNK pathway are mediated 
through activation of the Activator Protein-1 (AP-1) transcription factors.  The AP-
1 transcription factors are protein dimers composed of members of the Jun 
(cJun, JunB, JunD), Fos (cFos, FosB, Fra1, Fra2), Maf (cMaf, MafB, Maf G/F/K, 
Nrl), or ATF (ATF2, LRF1/ATF3, B-ATF, JDP1, JDP2) families, with cJun and 
cFos being the most studied.  The proteins form dimers through interactions of 
leucine zipper regions (Figure 2.4).  Members of the Jun family can form 
homodimers, or may form heterodimers with members of other families, most 
notably cFos.  AP-1 is activated by similar stimuli as mentioned above for the 
JNK signaling pathway.  In response to stress, growth factors, or a variety of 
other signals, the JNK MAPK cascade is activated, and subsequently activates 
the AP-1 transcription factor by translocating to the nucleus and phosphorylating 
distinct residues on the dimer.   The AP-1 dimer recognizes and binds to either 
the 12-O-tetradecanoylphorbol-13-acetate (TPA) response elements (5’-
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Figure 2.3.  The role of JNK in mitochondrial-mediated 
apoptosis.  JNK activation has been shown to be essential to 
mitochondrial-mediated, stress-induced apoptosis.  However, the 
exact targets for JNK have not been established.
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 TGAG/CTCA-3’) or the cAMP response elements (5’-TGACGTCA-3’) via a basic 
DNA binding domain, wherein the transcription factor proceeds to alter 
transcription of the target gene.  The target gene in question depends upon the 
original stimuli as well as the components of the dimer.  Therefore, the regulation 
and outcomes of AP-1 activity are extremely complex due to the large number of 
influential factors and are still being studied extensively. 
 AP-1 transcription factors have been shown to be involved in cellular 
proliferation, survival, and apoptosis.  As stated above, AP-1 is activated by 
growth factors, and numerous studies have shown that altering jun or fos affects 
cellular proliferation, both in cell culture and in animal models (Tong et al., 1998).  
For instance, overexpression of cFos and cJun proteins can lead to 
immortalization and transformation in both chicken and mouse embryo 
fibroblasts, respectively.  Additionally, transgenic mice with either c-fos-/- or a 
dominant negative cJun do not respond to tumor promoters, displaying a 
resistance to malignancy (Shaulian and Karin, 2001).  
On the other hand, AP-1 can also mediate apoptosis, as when activated 
by genotoxic stress, such as UV radiation or alkylating agents.  In neuronal cells, 
phosphorylation of cJun by JNK has been shown to be essential to the induction 
of AP-1-mediated apoptosis.  In addition, c-fos-/- mice have been shown to be 
resistant to apoptosis in retinal photoreceptors.  Numerous other gene knockout 
studies have shown that knockout of cjun can confer resistance to apoptosis.  
Further evidence for AP-1 mediated apoptosis has emerged through the 
discovery of proapoptotic target genes, including FasL and Bim (Shaulian and 
Karin, 2002).  As a result of the complexity of AP-1 induction and regulation, the 
outcomes of AP-1 transcription factor activation are diverse. 
 
2.3.5 Outcomes 
            JNK signaling has been implicated in various disease processes.  
Morishima et al. (2001) found that β-amyloid, when applied to cortical neurons,
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Figure 2.4  Components of the AP-1 transcription factor.  The 
AP-1 transcription factor is a dimer composed of members of the 
Jun and Fos families, as well as members of the Maf and ATF 
families.  The individual components form dimers through a leucine 
zipper dimerization domain, and bind DNA through a basic DNA-
binding region.  AP-1 transcription factors can bind to the TRE or 
CRE response elements. 
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activated JNK signaling, indicating a possible mechanism of neuronal cell damage 
in patients with Alzheimer’s disease.  Additionally, increases in immunoreactivity of 
cJun have been reported in apoptotic neurons in Alzheimer’s Disease (Anderson 
et al., 1996).  Zhang et al., (2003) found that JNK may mediate apoptosis in 
eosinophils, and the activation or inactivation of JNK signaling in response to 
cytokines may play a role in allergic responses.  JNK2 has been implicated in the 
formation of atherosclerotic lesions (Ricci et al., 2004).  Finally, studies with rats 
have shown that aging animals have increases in constitutive levels of cjun and 
cfos mRNA, indicating that the AP-1 complex may play a role in the aging process 
(Tong et al., 1998).   
 Because JNK signaling is essential to apoptosis in many cell types, and in 
particular in response to cellular stress, JNK signaling may be a beneficial target 
in disease management in either preventing inappropriate apoptosis or through 
induction of apoptosis in cancer cells.  Studies have begun to look at this 
possibility.  Jurkat leukemia cells underwent JNK-induced apoptosis in response 
to the drug pramanicin (Kutuk et al., 2005).  Zhang et al. (2003) suggested that 
by inducing JNK-mediated apoptosis, inflammation resulting from eosinophilia 
may be reduced in asthma and other allergic diseases.  Studies with rodent 
models of rheumatoid arthritis have shown that using the JNK inhibitor SP600125 
will prevent joint destruction by blocking the induction of matrix 
metalloproteinases, as well as possibly reducing the inflammatory response 
(Karin and Gallagher, 2005).  In the end, extensive studies will be required to 
determine if targeting JNK activity will be beneficial in treating diseases, because 
it is believed that blocking the detrimental effects of JNK will have the negative 
effect of also blocking the beneficial effects.  For instance, could blocking JNK-
induced apoptosis in the heart also result in the loss of JNK-mediated 
cardioprotective effects, only resulting in a different type of disease process?  
Similar problems must also be addressed concerning the targeting of AP-1.  
Future studies in animal models could answer some of these questions and lead 
to the development of pharmacological agents that could ameliorate JNK-
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mediated disease processes in humans.  So far, studies have not been 
successful in targeting JNK-induced inflammation in patients with Crohn’s 
disease (Waetzig and Herdegen, 2005).    
 
2.4 Oxidative Stress 
 
2.4.1 Background 
Basal levels of reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) are produced in all cell types by a variety of reactions (Figure 2.5).  
Endogenous antioxidants are involved in the removal of free radicals to alleviate 
potential damage.  Overproduction of free radicals due to disease processes or 
injury can lead to oxidation of proteins, lipids, and nucleic acids.  Subsequent 
cellular damage, including apoptotic cell death, has been linked to neurotoxicity.  
Additionally, the overproduction of free radicals can deplete endogenous 
antioxidants, causing more oxidative damage because the cell no longer has the 
capacity to remove free radicals (Lewen et al., 2000).   
 
2.4.2 Sources of ROS/RNS 
Many pathways in the brain result in the generation of free radicals (Figure 2.5).  
The major site of free radical production in the cell is the mitochondria via the 
electron transport chain.  During the production of adenosine triphosphate (ATP), 
the reducing equivalents (e-, H+, NADH, FADH2) are passed along the enzymes 
of the electron transport chain.  Under basal conditions, about 1-2% of the 
oxygen processed by the mitochondria is converted to superoxide (O2.-).  
However, disturbance of these mitochondrial enzymes, such as cytochrome c, 
due to injury or disease, can result in increased production of free radicals 
because electrons will be increasingly transferred to oxygen.  Increased Ca2+ 
influx can also lead to increased ROS through a similar process of enzymatic 
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Figure 2.5.  Sources of ROS/RNS.  Several pathways result in 
free radical production in the cell.  Overproduction of ROS/RNS can 
exhaust endogenous antioxidants, leading to lipid peroxidation, 
protein oxidation, and DNA/RNA oxidation.  This cellular damage 
can ultimately lead to apoptotic cell death.  L-arg=L-arginine; 
PGG2=prostaglandin G2; NOS=nitric oxide synthase.  
XDH=xanthine dehydrogenase; XO=xanthine oxidase.
Mitochondria
O2•-, etc.
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disruption due to calcium-induced alterations in the inner mitochondrial 
membrane (Lewen et al., 2000; Chinopoulos and Adam-Vizi, 2006).   
 A variety of sources of ROS/RNS exist outside the mitochondria.  One 
source of ROS is the phospholipase A2-cyclooxygenase pathway, which can lead 
to the production of superoxide in neurons, glia, microglia, and endothelial cells.  
Increases in intracellular Ca2+ can lead to the activation of nitric oxide synthase 
(NOS), leading to the production of nitric oxide (NO.), which can further react with 
superoxide to form peroxynitrite (ONOO-) in most cell types.  The conversion of 
xanthine dehydrogenase to xanthine oxidase can result in the formation of 
hydrogen peroxide (H2O2) in the endothelium.  Without sufficient removal of 
these free radicals by endogenous antioxidants, including glutathione, 
manganese superoxide dismutase (MnSOD), copper zinc superoxide dismutase 
(CuZnSOD), catalase, ascorbic acid, and vitamin E, ROS and RNS can cause 
cellular damage through lipid peroxidation, protein oxidation, and DNA/RNA 
oxidation (Lewen et al., 2000).   
 
2.4.3 Outcomes 
Oxidative stress has been linked to apoptosis in the brain following a 
variety of insults.  A key event is the release of cytochrome c from the 
mitochondria.  This loss leads to further production of ROS because of the 
disruption of the electron transport chain.  Cytochrome c interacts with other 
proapoptotic factors, including initiator caspase 9, Apaf-1, and ATP, which leads 
to the cleavage and activation of the effector caspase 3.  Active caspase 3 
proceeds to cleave products such as PARP, which when cleaved can no longer 
repair DNA.  Caspase 3 also activates nucleases that are involved in the 
cleavage of DNA during apoptosis.  In addition, cytosolic increases in ROS/RNS 
can activate proapoptotic factors in the cytoplasm, such as caspase 8, Bax, and 
Bid (Lewen et al., 2000).  Oxidative stress and the subsequent cellular damage 
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can also activate various signaling pathways that may or may not be involved in 
apoptosis (Leonard et al., 2004; Valencia and Moran, 2004).     
 Metals, such as mercury, have been implicated in the production of ROS 
(Leonard et al., 2004).  The most important free radical-generating reactions are 
the Fenton-type reaction and the Haber-Weiss reaction.  The Fenton reaction 
involves the reaction of a transition metal with H2O2 to form the highly reactive 
hydroxyl radical (.OH) and an oxidized metal ion.  In the Haber-Weiss reaction, 
an oxidized metal and superoxide (O2.-) react to form a reduced metal ion and 
O2, which then react with H2O2 to form .OH.  The resultant free radicals can 
cause metal-induced diseases, including cancer (Leonard et al., 2004).  ROS 
have been implicated in methylmercury-induced neurotoxicity (Ali et al., 1992). 
 One of the signaling pathways activated by both free radicals and metals 
is the JNK signaling pathway.  H2O2 has been shown to activate MAPK pathways 
directly, but also to inhibit phosphatases, which would lead to prolonged 
phosphorylation of MAPK signaling components (Leonard et al., 2004; Pham et 
al., 2005).  One mechanism through which oxidative stress may activate JNK 
directly is through the activation of apoptosis signal-regulating kinase 1 (ASK1), 
which is a MAPKKK.  ASK1 is normally complexed with thioredoxin (Trx) in the 
cytoplasm and in the mitochondria.  Trx is redox sensitive, and when Trx is 
oxidized, it releases ASK1, thus activating the enzyme, which can then activate 
downstream MAPKK, leading ultimately to apoptosis (Sumbayev and Yasinska, 
2005).   
AP-1 activity is also stimulated by oxidative stress, including H2O2 and 
superoxide.  Although the exact mechanism through which free radicals activate 
AP-1 has not been elucidated, the activation may be mediated through 
phosphorylation (Meyer et al., 1994; Tong et al., 1998; Leonard et al., 2004) or 
through redox-sensitive cysteine residues (Sun and Oberley, 1996). 
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CHAPTER III 
 
Methods 
 
3.1 Cell Line 
 
A human neuroblastoma cell line (SK-N-SH) obtained from American Type 
Culture Collection (HTB-11) was maintained in minimum essential medium 
(MEM) supplemented with 10% heat-inactivated fetal bovine serum, 1% 
antibiotics (penicillin/streptomycin/neomycin), 1% non-essential amino acids and 
1 mM sodium pyruvate.  Cells were grown at 37oC in a humidified atmosphere 
containing 5% CO2.  
 
3.2 Materials 
 
Thiosalicylic acid (minimum 95%), thimerosal (minimum 97% HPLC), 
Ponceau S, 12-O-tetradecanoylphorbol 13-acetate (TPA), sodium pyruvate, 3-
(4,5-dimethylthiazolyl-2-yl)-2,5-diphenyltetrazolium bromide, ethidium bromide, 
ethylenediaminetetraacetic acid (EDTA), and N-acetylcysteine were obtained 
from Sigma-Aldrich Chemical Corp. (St. Louis, MO).  Hoescht 33342, Trolox, and 
JNK inhibitor II (SP600125) was obtained from Calbiochem (San Diego, CA).  
Cell culture media, fetal bovine serum and antibiotics were obtained from 
Invitrogen Corp. (Carlsbad, CA).   
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3.3 Characterization of Cell Line 
 
The SK-N-SH cell line was examined to ensure that no significant changes 
occurred in the characteristics of the cell line as the cells were passaged over 
time.  The cell line was tested at both a low and a high passage for consistent 
doubling time and for changes in cellular markers.  All subsequent experiments 
were performed with cells with passage numbers in this established range. 
 
3.3.1 Doubling Time 
 
Cells were plated at a density of 5 X 104 cells per 60 mm plate, with the 
time of plating noted.  One experiment was performed at passage number 40 
and one at passage number 68.  Each subsequent day cells were trypsinized 
and counted on a hemocytometer, noting the time the count took place each day.  
The doubling time was determined by graphing the log of the cell number versus 
the time (in hours), then applying the following equation: 
 
 
 
where m=slope of the line.  The doubling time for cells at passage number 40 was 
26.9 hours (Figure 3.1), and the doubling time for cells at passage number 68 was 
25.7 hours (Figure 3.2). 
3.3.2 MAP2 and SYP 
            We chose to investigate if two different cellular markers remained 
unchanged during increasing cell passage numbers.  Both proteins were assessed 
at cell passage numbers 41 and 53 (Figure 3.3).  The first marker was microtubule-
associated protein-2 (MAP2), which is a stringent marker for neurons.  MAP2 is a   
1 
m 
x log2 Doubling time =
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Figure 3.1.  Low passage growth curve.  Cells were counted 
each day.  Number of cells counted and hour of cell count (time 
since initial plating) were used to determine doubling time, which 
was found to be 26.9 hours at passage number 40. 
Growth Curve-Passage No. 40
y = 0.0112x + 5.014
4.5
4.7
4.9
5.1
5.3
5.5
5.7
5.9
6.1
6.3
6.5
0 50 100 150
Time (hr)
Lo
g 
of
 C
el
l N
um
be
r
 
34 
 
Growth Curve Passage No. 68
y = 0.0117x + 5.0487
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Figure 3.2.  High passage growth curve.  Cells were counted 
each day.  Number of cells counted and hour of cell count (time 
since initial plating) were used to determine doubling time, which 
was found to be 25.7 hours at passage number 68.  
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structural protein that stimulates tubulin assembly, stabilizes microtubules, and 
affects spatial distribution of microtubules within cells.  MAP2, which migrates at  
about 300 kDa, remained unchanged throughout the passaging of the SK-N-SH 
cells (Figure 3.3A).  The second cellular marker that we examined was the 
synaptic vesicle protein synaptophysin (SYP).  SYP is an integral membrane 
protein that is involved in the formation of synaptic vesicles.  SYP levels remained 
unchanged throughout the passaging of the cell line (Figure 3.3B).   
3.4 Protein Analysis 
 
Protein content was measured with the BioRad protein assay, using 
bovine serum albumin (BSA) as the standard.  To determine the amount of 
protein in whole cell lysates, nuclear extracts, or cytoplasmic fractions from SK-
N-SH cells, 5 μL of sample (or a dilution if necessary) was added to 795 μL H2O 
in a 13x100 mm tube.  For protein analysis of whole cell lysates from luciferase 
samples, 20 μL of sample was added to 780 μL of H2O due to lower protein 
concentrations.  BioRad protein assay dye (200 μL) was then added to each tube 
for a total volume of 1 mL.  The samples were mixed on a vortex and allowed to 
incubate at room temperature for 5 minutes.  The BSA standards for the assay 
were made using a 50 mg/mL BSA stock solution to make a 50 μg/mL BSA 
working solution.  Protein standards for the standard curve were prepared by 
making serial dilutions from the working solution.  As with samples, 200 μL 
BioRad protein assay dye was added to each tube, and the samples were mixed 
on a vortex.  Absorbance of standards and samples was read at 595 nm using 
the Versamax spectrophotometer and SpotMax Software (Molecular Devices, 
Sunnyvale, CA).  Software determined protein content of samples based on 
optical density values on standard curve.  
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MAP2
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Figure 3.3.  Characterization of SK-N-SH cell line.  Microtubule-
associated protein-2 (MAP2), a stringent marker for neurons, and 
synaptophysin (SYP), an integral membrane protein that is 
involved in the formation of synaptic vesicles, were assessed with 
Western blotting of whole cell lysates of cells at passage 41 and 
53.  50 μg of protein loaded each lane. 
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3.5 Treatment of Cells with Thimerosal 
 
Cells were treated with a range of thimerosal concentrations (0-10 μM), 
and thiosalicylate was used as a control to ensure that changes noted following 
treatment were attributed to the mercury-containing portion of the thimerosal 
molecule.  The concentration of thiosalicylate corresponded to the highest 
concentration of thimerosal used in each individual experiment.  A stock solution 
of 1 mM thimerosal or thiosalicylate was prepared in medium and appropriate 
dilutions were made to achieve the final treatment concentrations for each 
experiment.   
 
3.6 Cell Viability Assays 
 
3.6.1 Lactate Dehydrogenase (LDH) Assay 
 
Cells were seeded in 2 mL of media in 6-well plates.  At 80-90% 
confluency, cells were treated 0-10 μM thimerosal in replicates of three.  Cells 
were incubated for 24 or 48 h, followed by removal of medium and centrifugation 
to pellet floating cells.  The supernatant was removed and placed in a separate 
tube on ice.  Five hundred microliters of 0.2% Triton X was added to each well, 
and cells were scraped and added to the cells pelleted from the medium.  Each 
well was washed with 500 μL of water, which was also added to the tube with the 
cells.  The tubes were vortexed for 1 min, centrifuged, and placed on ice.  β-
NADH solution was prepared by dissolving 2 mg β-NADH in 28.5 mL of 0.1 M 
potassium phosphate buffer (pH 7.5).  Fifty microliters of sample was added to 
920 μL β-NADH solution and incubated at room temperature for 20 min.  After 
incubation, 30 μL of 22.7 mM sodium pyruvate solution was added and the 
absorbance was read at a wavelength of 340 nm at 25°C.  Readings were taken 
every 15 s for 2 min (Stasar II, Gilford, Nova Biotech, El Cajon, CA) to determine 
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the absorbance change per min, which was used to calculate LDH activity with 
the following equation:   
LDH activity (μmol/L) = dA/min/6.22/0.05 X 1000  
where dA is the change in absorbance (Loo and Rillema, 1998).  The LDH 
activity of the medium was compared to the total LDH activity (total of tissue and 
medium). 
3.6.2 MTT Assay 
 
Cells were seeded in a 96-well flat-bottom plate at a density of 4 X 104 
cells per well in 100 μL of medium.  After 24 h, thimerosal-containing medium 
was added to the cells with final concentrations of 0-10.0 μM in a total volume of 
200 μL.  Cells were treated in replicates of five wells each with medium used as a 
blank.  Cells were treated for either 24 or 48 h.  3-(4,5-dimethylthiazolyl-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was prepared by dissolving 5 mg/mL in 
phosphate buffered saline (PBS; pH 7.4) and then sterile filtered.  Four hours 
before the end of the incubation period, 10 μL of MTT was added to each well.  
At the end of the treatment period, 100 μL of 0.1 N isopropanol/HCl was added to 
each well and mixed by repeated pipetting to dissolve granules.  Absorbance 
was measured on a plate reader (Molecular Devices Corp., Sunnyvale, CA) at a 
wavelength of 570 nm (Mosmann, 1983).  Results were reported as percentage 
of control.   
 
3.7 Fluorescent Microscopy 
 
SK-N-SH cells were plated in 6-well plates at a density of 5 x 105 cells per 
well.  After 24 h, medium was removed and replaced with fresh media containing 
either thiosalicylate (5 µM) or thimerosal (5 µM).  At the end of the treatment 
period (24 h), medium was removed from each well, placed in 50 mL tubes, and 
stored on ice.  Wells were washed twice with PBS, and each time the PBS was 
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combined with the corresponding medium on ice.  After the washes, 2 mL of 1 
mM EDTA (in PBS) was added to each well and allowed to incubate at room 
temperature until cells were floating.  This suspension was then added to the 
appropriate tubes on ice.  Tubes were centrifuged at 200 x g for 10 min.  The 
supernatant was discarded, cells were washed in 1 mL PBS, and centrifuged as 
previously described.  After removal of the supernatant, cells were resuspended 
in 100 µL PBS.  Cells were then stained in suspension with Hoescht 33342 (2 
µg/mL) and ethidium bromide (5 µg/mL) for 15 min.  Cells were examined at 380 
nm using a Microphot-SA microscope (Nikon) and Spot RT Software (Spot 
Diagnostic Instruments, Inc., Sterling Heights, MI) (Katsen et al., 1998).  
Apoptotic cells were identified by nuclear condensation and DNA fragmentation 
(Squier and Cohen, 2000).   
 
3.8 Cell Counts for Apoptotic and Necrotic Cells 
 
 Cell counts were performed on fluorescently stained slides as above after 
24 h treatment and counted on the same microscope.  For each treatment 100 
cells were counted, and each experiment was performed three times.  Statistical 
analysis was performed as indicated below.  Apoptosis was assessed by nuclear 
fragmentation and condensation, and necrosis was assessed by swelling and 
uptake of ethidium bromide (pink color).   
 
3.9 Isolation of Cytoplasmic Fractions, Nuclear Extracts, and Whole Cell Lysates 
 
Cytoplasmic fractions, nuclear extracts, and whole cell lysates were 
prepared by washing cells twice in cold PBS.  For whole cells lysates, cells were 
resuspended in phosphate lysis buffer, vortexed, and frozen prior to analysis.  
For cytoplasmic fractions and nuclear extracts, cells were initially resuspended in 
lysis buffer (10 mM HEPES-KOH, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM 
dithiothreitol (DTT), 5 mM NaF, 1 mM Na3VO4, Complete Mini (15%; Roche, 
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Indianapolis, IN), H2O) and incubated on ice for 15 min.  After incubation, 10% 
NP-40 was added, the suspension was vortexed for 15 sec and centrifuged for 
30 sec at 14,000 rpm.  The supernatant, containing the cytoplasmic fraction, was 
removed and frozen at –80˚C until analyzed.  The pellet was resuspended in a 
second buffer (20 mM HEPES-KOH, 1.5 mM MgCl2, 420 mM NaCl, 35% glycerol, 
0.5 mM DTT, 5 mM NaF, 1 mM Na3VO4, Complete Mini (15%), H2O) and 
incubated on ice for 20 min.  The suspension was then centrifuged at 12,000 rpm 
for 2 min.  The supernatant, containing the nuclear extract, was removed and 
frozen at –80˚C until analyzed.   
 
3.10 Subcellular Fractionation 
 
The mitochondrial fraction of SK-N-SH cells was prepared by washing the 
cells twice in cold PBS, followed by resuspension in 5 ml of 0.25 M sucrose, 1 
mM ethylene glycol tetra acetic acide (EGTA), and 10 mM Tris-HCl (pH 7.4) and 
centrifuging at 500 x g for 2 min at 4oC.  The supernatant was discarded and the 
cells were resuspended in 5 ml of the same buffer.  The cells were homogenized 
in a glass Teflon homogenizer using 10 up-and-down strokes at 500 rpm.  The 
homogenate was centrifuged at 1500 x g for 10 min at 4oC.  The supernatant 
was removed and recentrifuged at 10,000 x g for 10 min.  The pellet, which 
contained mitochondria, was resuspended in 50 μL of buffer.  The supernatant 
was recentrifuged at 100,000 x g (4oC, 1 h) to generate the S-100 fraction.  
Protein concentration of both fractions was determined by a colorimetric assay 
(BioRad Laboratories, Hercules, CA).   
 
3.11 Caspase-3 Protease Activity   
 
Activation of caspase 3 was determined using the ApoAlert assay kit 
(Clontech Laboratories, Palo Alto, CA), which fluorometrically detects caspase 3 
activity using proteolytic cleavage of the fluorophore 7-amino-4-trifluoromethyl 
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coumarin (AFC) from the substrate conjugate DEVD-AFC.  Cells were plated (6 x 
105) in 100 mm dishes and treated with 0-5 μM thimerosal for 0-24 h.  Cells (2 x 
106) were collected at various time points after treatment, lysed on ice, 
centrifuged (12,000 rpm x 3 min) and the supernatants were collected and stored 
at -70oC until further use.  Cell lysates were incubated with DEVD-AFC in the 
presence of dithiothreitol for 1 h at 37oC.  Detection of AFC was measured using 
a 400 nm excitation filter and a 530 nm emission filter.  Caspase 3 activity is 
expressed as percent control.   
 
3.12 Western Analysis 
 
Cytoplasmic (p-JNK, glyceraldehyde-3-phosphate dehydrogenase 
[GAPDH]), nuclear extracts (p-JNK, cJun, cFos, p-cJun(Ser63), p-cJun(Ser73), β-
actin) or whole cell lysates (Bim/BOD, Cleaved Caspase 3, Caspase 9, PARP, 
MAP2, SYP, GAPDH) were electrophoresed on a 7% (MAP2 only) or 12.5% SDS-
PAGE (SDS-polyacrylamide gel electrophoresis) according to the method of 
Laemmli (1970) and transferred to nitrocellulose membrane.  Transfer efficiency 
was assessed by staining with 0.1% Ponceau S, and then blots were washed with 
distilled water to remove stain.  Blots were blocked for 1 h at room temperature in 
Blotto (5% milk, 10 mM Tris-HCl, 150 mM NaCl (pH 8.0), 0.05% Tween-20) or 5% 
dry milk in TBST (10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20 [pH 8.0]; p-JNK, 
p-cJun [Ser63], p-cJun [Ser73]).  Each blot was incubated overnight at 4°C with 
the primary antibody at a dilution of 1:1000 in Blotto (cJun, cFos, Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA; Bim/BOD, Stressgen, Victoria, British 
Columbia, Canada; Cleaved Caspase 3, Caspase 9, PARP, Cell Signaling 
Technology, Inc., Beverly, MA; MAP2, Chemicon International, Temecula CA; 
SYP, Santa Cruz Biotechnology, Inc.; GAPDH (1:10,000), Trevigen, Gaithersburg, 
MD; β-actin (1:10,000), Sigma-Aldrich Chemical Corp., St. Louis, MO) or 5% 
bovine serum albumin (BSA) in TBST (p-JNK, p-cJun(Ser63), p-cJun(Ser73), Cell 
Signaling Technology, Inc., Beverly, MA). The next day each blot was washed 
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twice with TBST and then incubated with an anti-mouse IgG (1:10,000) or anti-
rabbit IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology, 
Santa Cruz, CA) at a 1:3000 dilution in Blotto or 5% milk solution in TBST (p-JNK, 
p-cJun[Ser63], p-cJun[Ser73]) for 1.5 h at room temperature.  Protein bands were 
then visualized using the enhanced chemiluminescence detection system 
(Amersham, Little Chalfont, UK).  All Western blots in Results section are 
representative of at least three experiments.   
3.13 Transient Transfection 
 
Cells were plated at a density of 3 x 106 cells per 100 cm plate and grown 
overnight.  Cells were transfected using the calcium phosphate method, and 
were transfected with the pGL2 empty vector or with 1 μM of the AP-1 construct, 
or co-transfected with the AP-1 construct and either A-Fos (0.125 μg or 0.25 μg) 
or TAM67 (0.25 μg or 0.5 μg).  The AP-1 construct, which was a generous gift 
from Dr. Richard Niles, consists of four consensus sequences inserted into the 
pGL2 vector (Promega, Madison, WI).  The A-Fos construct is a dominant 
negative consisting of an N-terminal acidic extension added to cFos and cloned 
into the CMV-500 vector (Steinmuller et al., 2001).  This construct was a 
generous gift from Dr. Charles Vinson (National Institutes of Health).  The TAM67 
construct is a cJun dominant negative that lacks the transactivation domain and 
was cloned into the pcDNA3.1(-) vector (Brown et al., 1994).  This construct was 
a generous gift from Dr. Michael Birrer (National Institutes of Health).  Both 
dominant negative forms retain the ability to dimerize with cJun and cFos 
proteins and bind DNA; however, structural alterations prevent AP-1-mediated 
transcriptional events.  Seven hours after transfection, cells were washed twice 
with phosphate buffered saline (PBS; 137 mM sodium chloride, 3 mM potassium 
chloride, 1 mM potassium phosphate, and 10 mM sodium phosphate), and fresh 
media was added.  On the following day, cells were trypsinized and plated in 24-
well plates at a density of 1.5 x 105 cells per well.  Twenty-four hours later cells 
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were treated in triplicate with 0-2.5 μM thimerosal or 100 nM TPA.  After 24 h, 
cells were washed with PBS and lysed using 200 μL of Passive Lysis Buffer 
(Promega).  Reporter assays were performed using the Luciferase Assay System 
(Promega) and TD-20/20 Luminometer (Turner Designs, Sunnyvale, CA).   
 Additional experiments were conducted using cells co-transfected with 
AP-1 and 0.5 μg TAM67.  Following transfection as above, these cells were 
plated in 100 mm dishes at a density of 1 x 106 cells per plate.  After 24 h, cells 
were treated with either 2.5 μM thiosalicylate (control) or thimerosal for 24 h, and 
then whole cell lysates were collected and analyzed by Western blotting.  All 
transient transfection experiments were performed at least three times.   
 
3.14 Treatment with JNK Inhibitor II (SP600125) 
 
SP600125 is an anthrapyrazolone compound that is a JNK-specific, 
reversible, ATP-competitive inhibitor (Bennett et al., 2001).  Preliminary studies 
were conducted to determine the lowest concentration of SP600125 needed to 
block thimerosal-mediated phosphorylation of cJun (Figure 3.4).  Based on visual 
examination of Western blotting for cJun (Ser 73), all further experiments were 
carried out using 10 μM JNK inhibitor II (SP600125) or equal volumes DMSO 
(vehicle) prior to thimerosal treatment (2 h pretreatment). 
 
3.15 Treatment with Trolox 
 
Trolox (TX) is a vitamin E analog with antioxidant properties.  Trolox was 
prepared by dissolving in 100% ethanol to make a 0.5 M stock solution.  Cells 
were pretreated for 2 h with 1 mM Trolox or equal volumes ethanol (vehicle) 
before thimerosal treatment was added.   
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Figure 3.4 Determination of JNK inhibitor II (SP600125) 
concentration. SK-N-SH cells were treated with 5 μM 
thiosalicylate with DMSO (Lane 1) or with 10 μM SP600125 (Lane 
2) or with 5 μM thimerosal with DMSO (Lane 3) or 1 μM (Lane 4), 5 
μM (Lane 5), or 10 μM (Lane 6) SP600125.  Cytosolic samples 
were assessed with Western blotting for phosphorylated cJun (Ser 
73) to determine the lowest concentration of SP600125 that 
reduced JNK activity as seen by a decrease in phosphorylation of 
cJun. 
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3.16 Treatment with N-Acetylcysteine 
 
N-Acetylcysteine (NAC) is a precursor in glutathione synthesis, as well as 
a thiol-containing molecule capable of binding to thimerosal.  NAC was prepared 
by dissolving in medium to make a 0.5 M stock solution.  Cells were pretreated 
for 2 h with 1 mM NAC.  Prior to treatment NAC was removed.  Then cells were 
treated with thiosalicylate or thimerosal (no NAC pretreatment), or thimerosal 
with or without NAC added back to treatment, and NAC alone.   
 
3.17 Statistical Analysis 
 
Statistical analysis was performed using SigmaStat software (SPSS, Inc., 
Chicago, IL).  Results were assessed with t-test or analysis of variance using 
Tukey’s test or Dunnett’s test with a p-value of 0.05.    
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CHAPTER IV 
 
Results 
 
4.1 Morphological Changes Upon Thimerosal Treatment 
 
To determine if thimerosal induced toxicity in a human neuroblastoma cell 
line (SK-N-SH), cells were treated with a range of concentrations (0-5 μM), and 
then visualized and photographed using a Nikon Phase Contrast microscope.  
Within 2 h of exposure, membrane alterations could be visualized, followed by 
cell shrinkage and detachment (Figure 4.1).  Observed morphological changes 
upon thimerosal administration were consistent with reports of mercurial-
mediated cytoskeletal toxicity (Duhr et al., 1993; Kinoshita et al., 1999).  In this 
model, we showed cytoskeletal changes at concentrations of thimerosal 
significantly below those previously reported by Kim et al. (2002) in treatment of 
HeLa S cells (20 μM).  Additionally, morphological changes such as those 
described above suggest that thimerosal may induce apoptotic cell death (Lincz, 
1998). 
4.2 Lactate Dehydrogenase (LDH) Assay 
 
 To further evaluate toxicity, activity of LDH, a cytosolic enzyme released 
into surrounding media during cell death, was measured.  LDH is a ubiquitous 
enzyme involved in the conversion of lactate to pyruvate, as well as the reverse 
reaction, during glucose metabolism.   
 
 
 
Pyruvate + NADH + H+ LDH Lactate + NAD+ 
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Figure 4.1.  Thimerosal induces cytoskeletal and membrane 
changes. Morphological analysis of SK-N-SH cells following 
treatment with either A) 5 μM thiosalicylate for 6 h; B) 5 μM
thimerosal for 2 h; C) 5 μM thimerosal for 4 h and D) 5 μM
thimerosal for 6 h.  No changes in morphology were noted in the
thiosalicylate treated cells, whereas thimerosal caused alterations 
of membranes (arrow).  In addition, cell shrinkage and detachment 
occurred within 6 h of treatment.  Cells were visualized and 
photographed using a Nikon Phase Contrast Microscope.  
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As the membrane loses integrity during necrosis and late apoptosis, LDH is 
released.  This assay approximates cell death rates by measuring enzymatic 
activity of LDH as it converts pyruvate and NADH to lactate and NAD+ (Loo and 
Rillema, 1998).  The LDH assay indicated a concentration- and time-dependent 
thimerosal-induced toxicity.  At 24 h, LDH activity was significantly higher (p < 
0.001) than control at 2.5, 5.0, and 10.0 μM thimerosal treatments, indicating a 
loss of membrane integrity (Figure 4.2A).  Extending the exposure time to 48 h 
also caused a significant increase in LDH activity with 1.0 μM thimerosal (Figure 
4.2B). 
 
4.3 3-(4,5-dimethylthiazolyl-2-yl)-2,5-diphenyltetrazolium Bromide (MTT) Assay 
 
 
The MTT assay is a colorimetric assay for cytotoxicity.  MTT is cleaved to 
a blue formazan product by dehydrogenase enzymes of intact mitochondria, 
allowing for determination of cell viability (Mosmann, 1983).  As with the LDH 
assay, thimerosal treatment of SK-N-SH cells induced toxicity in a concentration- 
and time-dependent manner.  At 24 h, cell viability was significantly decreased 
with 5.0 and 10.0 μM thimerosal in comparison to the control (Figure 4.3A).  At 
48 h, cell viability was also significantly decreased at 1.0 μM and 2.5 μM 
concentrations (Figure 4.3B).  Results from the MTT experiments paralleled 
those obtained with the LDH assay in that extended exposure times with lower 
thimerosal concentrations also led to cytotoxicity.   
 
 
4.4 Fluorescent Analysis of Cell Death 
 
            LDH leakage can occur as a result of late stage apoptosis or necrosis.  
Therefore, we used fluorescence microscopy with DNA staining to determine if one 
or both types of cell death were occurring as a result of thimerosal exposure.   
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Figure 4.2. Thimerosal treatment induces LDH release from 
SK-N-SH cells.  Enzymatic activity of LDH in medium was 
measured at 24 and 48 h in cells treated with a range of
thimerosal concentrations (0-10.0 μM) or 10.0 μM thiosalicylate.  
Results are presented as percentage of LDH activity in medium in
comparison to total LDH activity (total of tissue and medium).  
+P<0.001.  Results shown are representative of at least three 
experiments at each time point. 
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Figure 4.3.  Thimerosal-treated cells show decreased cell 
viability. Cell survival was determined by the MTT assay at 24 
and 48 h in cells treated with a range of thimerosal concentrations 
(0-10.0 μM) compared to control (10.0 μM thiosalicylate).  
*P<0.05; +P<0.001, n=6 (for each time point).  
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Fluorescent analysis of cell death as described by Katsen et al. (1998) and 
Thevenod et al. (2000) was conducted using both Hoescht 33342, which is 
membrane permeable, and ethidium bromide, which is not membrane 
permeable.  Under ultraviolet epi-illumination necrotic cells fluoresce pink due to 
ethidium bromide uptake, whereas normal and apoptotic cells emit blue 
fluorescence due to Hoescht 33342 incorporation.  Apoptotic cells, distinguished 
from normal cells based on condensation and fragmentation of nuclei, are 
depicted in Figure 4.4 (arrows).  In addition, several cells stained with ethidium 
bromide, suggesting that a 24 h exposure to 5 μM thimerosal results in both 
apoptotic and necrotic morphologies.  However, some of these cells were small 
and round, rather than large and swollen, which may indicate that instead of 
being necrotic cells, some of these cells showing pink fluorescence were actually 
apoptotic bodies.   
 
 
4.5 Cell Counts for Apoptotic and Necrotic Cells 
 
 
            Cell counts for apoptotic and necrotic cells indicated that the number of 
apoptotic cells was significantly increased following 2.5 and 5 μM thimerosal 
treatment for 24 h in comparison to control.  On the contrary, the number of 
necrotic cells at both concentrations was not significantly different from control 
(Figure 4.5). 
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Control 5 μM Thimerosal
Figure 4.4.  DNA staining shows thimerosal-induced 
apoptosis. Cells were analyzed by fluorescence microscopy using 
Hoescht 33342 and an ethidium bromide counterstain after a 24 h 
exposure of either 5 μM thiosalicylate or thimerosal.  Normal and 
apoptotic nuclei stain blue, and nuclei stain pink in cells upon loss 
of membrane integrity (necrosis or late apoptosis).  Arrows indicate 
DNA fragmentation and condensation in cells receiving 5 μM
thimerosal.   
24 h
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Figure 4.5.  Thimerosal induces apoptosis.  Apoptotic cells were 
increased significantly following both 2.5 and 5 μM thimerosal (TM) 
treatment at 24 h.  Fluorescently stained cells were assessed for 
either apoptotic (condensed and fragmented nuclei) or necrotic 
(swelling and uptake of ethidium bromide) characteristics.  One 
hundred cells were counted per treatment. *P<0.001. N=3.
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4.6 Thimerosal Causes Cytochrome c Translocation from the Mitochondria to the 
Cytosol 
 
Both inorganic and organic mercurials have been shown to rapidly 
accumulate in mitochondria, resulting in dysfunction.  Since the SK-N-SH cells 
treated with thimerosal appeared apoptotic, we chose to investigate if the cell  
death cascade was associated with mitochondrial release of proapoptotic 
proteins.  As shown in Figure 4.6, a rapid increase in the cytosolic content of 
cytochrome c was observed after thimerosal administration.  
 
 
4.7 Thimerosal Induces Caspase 9 Cleavage 
 
 
In the mitochondrial-initiated pathway of apoptotic cell death, caspase 
activation is achieved after the release of cytochrome c from mitochondria.  Upon 
release of the proapoptotic proteins from the mitochondria, a multimeric protein 
complex consisting of Apaf-1 and cytochrome c forms, followed by recruitment 
and activation of procaspase 9.  Procaspase enzymes can be activated after they 
are cleaved; therefore, we examined the cleavage pattern of caspase 9 in cells 
treated with thimerosal.  Within 8 h of thimerosal treatment (1.0-5.0 μM) 
increased generation of a 34 kDa band (Figure 4.7) was observed in addition to 
the parent form of caspase 9 (46 kDa).   
 
4.8 Thimerosal Induces Caspase 3 (CPP-32) Cleavage 
 
Caspase 3 is a downstream target for caspase 9 activity; therefore, we 
examined by Western analysis the cleavage patterns of caspase 3 following 
thimerosal treatment.  After 24 h of treatment, both the 17 and 19 kDa caspase 3 
cleavage products were observed (Figure 4.8). 
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Mitochondria Cytosol
0          1              5           0           1            5      μM thimerosal
Cytochrome c
Figure 4.6.  Cytochrome c release following thimerosal 
treatment.  Cells were treated with 0-5 μM thimerosal for 6 h.  
Twenty micrograms of mitochondrial protein or 40 μg of the 
cytoplasmic fraction was analyzed for cytochrome c by Western 
analysis.  By 6h, cytochrome c levels in the cytoplasm were 
increased. 
6 h
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Procaspase 9  
(46kDa)
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(34 kDa)
1 h                 4 h           8 h
0       1       5     1      5      1       5     μM thimerosal
Figure 4.7.  Caspase 9 cleavage following thimerosal 
treatment. Caspase 9 cleavage was determined by Western 
analysis in cells receiving thimerosal (0-5 μM) or thiosalicylate (5 
μM) for 1 h, 4 h, and 8 h.  Caspase 9 cleavage was increased at 8 
h. 
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Figure 4.8.  Thimerosal induces cleavage of caspase 3.  Cells 
were treated with 1 or 5 μM thimerosal or 5 μM thiosalicylate (Ct) 
for 24 h.  Cytosolic fractions were analyzed with Western blotting to 
detect caspase 3 cleavage products and procaspase (32 kDa).  
Cleavage products were detected at 24 h following 5 μM thimerosal 
treatment. 
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Procaspase 3 
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4.9 Caspase 3 Activity Increases in a Concentration- and Time-dependent Manner 
 
The activity of caspase 3 during thimerosal-induced apoptosis in SK-N-SH 
cells was measured using the ApoAlert assay kit by Clontech.  Cells were treated 
with 0-5 μM thimerosal and samples were collected at various time points from 0-
24 h.  Figure 4.9 shows a concentration- and time-dependent increase in 
caspase 3 activity.  At 6 h caspase 3 activity had increased 12 fold in the 5 μM 
treated cells with no increase noted at 1 μM thimerosal.  At 24 h both 1 and 5 μM 
treated cells had significantly higher caspase 3 activity than control, 16 and 22 
fold, respectively.  The increase in caspase 3 activity paralleled the cleavage 
pattern observed in Figure 4.8.  The use of the fluorescence-based ApoAlert 
assay provided greater sensitivity than Western analysis, allowing detection of 
changes in caspase 3 activation at earlier time points.  Caspase cleavage was 
easily detected by Western analysis at the 24 h time point, consistent with the 
fluorescent-based assay.    
      Caspase 8 can activate caspase 3 independent of mitochondrial events 
leading to apoptosis; however, in our studies we found no activation of caspase 8 
(data not shown), suggesting initiation of cell death signals by thimerosal at the 
level of the mitochondria.   
 
4.10 Thimerosal Induces Poly(ADP-ribose) Polymerase (PARP) Cleavage 
 
PARP, a DNA nick sensor, is a substrate for cleavage by activated 
caspase 3.  The data shown in Figure 4.10 indicates that thimerosal induces 
PARP cleavage.  At 24 h, 5 μM thimerosal treatment caused degradation of the 
116 kDa parental PARP protein accompanied by generation of          
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Figure 4.9.  Caspase 3 activity. SK-N-SH cells were treated with 
0-5 μM thimerosal for 1 h, 6 h, or 24 h. The ApoAlert fluorescence 
detection assay was used to determine caspase 3 activity.  
Caspase 3 activity was detected at 6 h following 5 μM thimerosal 
treatment, and at 24 h following 1 and 5 μM thimerosal treatment. 
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Parental PARP 116 kDa
Cleaved PARP 85 kDa
0         2.5      5.0   μM Thimerosal
Figure 4.10. Thimerosal induces cleavage of PARP. PARP, a 
116 kDa downstream target of activated caspase 3, was analyzed 
by Western analysis in cells receiving 0-5 μM thimerosal.  Cells 
treated with 5 μM thiosalicylate showed minimal cleavage; whereas 
SK-N-SH cells receiving thimerosal contained an abundant 85 kDa
cleavage product after 24 h.  
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an 85 kDa immunoreactive cleavage product (Figure 4.10).  No cleavage was 
observed following 12 h of treatment with 1 μM thimerosal (data not shown). 
 
4.11 Thimerosal Induces Phosphorylation of JNK 
 
The JNK pathway is activated by cellular stresses, resulting in the 
phosphorylation of cJun N-terminal kinase, which then phosphorylates proteins, 
including transcription factors.  To determine if thimerosal activates this signaling 
pathway, SK-N-SH cells were treated with a range of thimerosal concentrations (0-
10 μM) for 2 and 4 h.  Western blotting showed an increase of JNK 
phosphorylation at 5 and 10 μM at both time points in comparison with 
thiosalicylate (Figure 4.11).  The activated JNK was present in both the cytoplasm 
(Figure 4.11A) and the nucleus (Figure 4.11B).  Multiple bands are visible, and 
may be because the three JNK genes encode 10 JNK isoforms, and these splice 
variants migrate at either 46 kDa or 54 kDa (Davis, 2000). Lower concentrations of 
thimerosal required longer incubation times to activate JNK.  For instance, cells 
treated with 2.5 μM thimerosal began to show increases in p-JNK at 6 h (Figure 
4.11C).  This MAPK induction was specific for JNK; p38 and extracellular signal-
regulated kinase (ERK) were not activated in response to thimerosal (data not 
shown).  Activated JNK in the nucleus is significant because this is a potential site 
of interaction with transcription factors, including AP-1.  Activated JNK in the 
cytoplasm is also important because this is a second site of interaction with cellular 
components, including proteins mediating apoptosis.   
4.12 Thimerosal Treatment Causes Increases in cJun and cFos 
 
Activator Protein-1 most often consists of dimerized proteins from the cJun 
and cFos families.  Transcription factors from the cJun family can form either 
homodimers or heterodimers with members of the cFos family.  To determine if 
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Figure 4.11.  Thimerosal induces phosphorylation of JNK. 
Cells were treated with a range of thimerosal concentrations (0-10 
μM) for 2 and 4 h.  Western analysis was performed to assess 
increases in phosphorylation of JNK in both cytoplasmic samples 
(A) and nuclear extracts (B) in comparison to control (Ct; 150 μg
protein per lane-cytoplasmic samples; 40 μg protein per lane-
nuclear extracts).  Cells were also treated with 2.5 μM thimerosal
for 6 h and Western analysis was performed on both nuclear 
extracts and cytoplasmic samples (C) in comparison to control (75
μg protein per lane-cytoplasmic samples; 50 μg protein per lane-
nuclear extracts).  GAPDH (A) or β-actin (B and C) was used as a 
loading control.
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Figure 4.12.  Thimerosal causes increases in cJun and cFos 
levels. Western blotting of nuclear extracts showed that cells 
treated with 5 μM thimerosal for 4 h and 10 μM thimerosal for 2 or 
4 h had increases in total cJun (A) and cFos (B) levels, with cJun
also showing an increase with 2.5 μM at 4 h.  40 μg of protein 
loaded per lane. β-actin was used as a loading control.
β-actin
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protein levels of either cJun or cFos were increased in response to thimerosal 
exposure, we treated SK-N-SH cells with a range of thimerosal concentrations (0-
10 μM) for 2 and 4 h and collected nuclear extracts.  Western blotting of nuclear 
extracts showed that cells treated with 10 μM for 2 h had increases in total cJun 
and cFos levels (Figure 4.12).  Extending treatment time to 4 h showed increases 
in cJun levels with 2.5-10 μM thimerosal treatment in comparison to control (Figure 
4.12A), while cFos levels were increased with 5-10 μM thimerosal treatment 
(Figure 4.12B).  However, increased protein levels do not necessarily indicate 
activation of transcription factors, which must first be phosphorylated to be 
activated.   
4.13 Thimerosal Induces Phosphorylation of cJun (Ser 63 and Ser 73) 
 
Phosphorylation of cJun, which indicates activation, was determined 
following thimerosal treatment.  Nuclear extracts of SK-N-SH cells treated with a 
range of thimerosal concentrations (0-10 μM) for 2 and 4 h showed an increase in 
cJun phosphorylation at 5 and 10 μM at both time points in comparison with 
control (Figure 4.13).  cJun phosphorylation was increased at both serine 63 
(Figure 4.13A) and serine 73 (Figure 4.13B); phosphorylation of both sites has 
been shown to maximally enhance cJun activity (Smeal et al., 1991).   
4.14 Thimerosal Activates AP-1 Transcriptional Activity Through cJun But Not 
cFos 
 
 To further investigate the activation of the JNK/AP-1 pathway, we next 
looked at AP-1 transcriptional activity.  We transfected SK-N-SH cells with the 
pGL2 empty vector or the AP-1 construct using a luciferase reporter assay system.  
Cells treated with 2.5 μM thimerosal showed a significant increase in luciferase 
activity, indicating an increase in AP-1 transcriptional activation.  Transfected cells
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Figure 4.13.  Thimerosal causes activation of cJun. Cells 
treated with 5 and 10 μM thimerosal showed increases in
phosphorylation of cJun in nuclear extracts at 2 and 4 h at both 
serine 63 (A) and serine 73 (B) in comparison to control, as well as 
an increase at 2.5 μM thimerosal at Ser 73.  25 μg of protein 
loaded per lane. β-actin was used as a loading control.
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were also treated with 100 nM TPA, a known activator of AP-1 transcriptional 
activity that served as a positive control (Figure 4.14, 4,15).  We next used the A-
Fos dominant negative to determine the role of cFos in this pathway.  Cells 
transfected with the AP-1 luciferase reporter construct alone or cotransfected with 
(0.125 μg or 0.25 μg) A-Fos showed comparable increases in luciferase activity, 
suggesting that cFos is not part of this AP-1 complex activated by thimerosal 
(Figure 4.14).  The TPA-induced increase in luciferase activity was inhibited, 
indicating that the A-Fos construct was able to block AP-1 transcriptional activity 
(Figure 4.14).  The TAM67 dominant negative was used to determine the role of 
cJun in this pathway.  Cells cotransfected with the cJun dominant negative and 
AP-1 luciferase reporter construct did not show increases in luciferase activity 
following thimerosal treatment, indicating blockage of AP-1 transcriptional activity 
(Figure 4.15).  This suggests that cJun is playing an active role in thimerosal-
induced AP-1 transcriptional activation, possibly by forming a homodimer. 
4.15 Thimerosal Treatment Increases Levels of Proapoptotic Bim 
 
Bim is a proapoptotic member of a subgroup of the Bcl2 family of proteins 
that contain only the Bcl2-homology 3 (BH3) domain.  These proteins interact 
with and inactivate anti-apoptotic Bcl2 family members in response to cellular 
stress, such as DNA damage (Bouillet et al., 2001).  Bim may also be directly 
activated by JNK, leading to mitochondrial-mediated apoptosis. Additionally, Bim 
is an AP-1 target gene; therefore, we wanted to determine if Bim was associated 
with thimerosal-induced toxicity in this cell line.  In cells treated with 2.5 μM 
thimerosal for 24 h, Western blotting showed that Bim levels were increased in 
comparison with control (Figure 4.16A, Lanes 1 and 3).   
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Figure 4.14. Thimerosal treatment increases AP-1 
transcriptional activation, but does not involve cFos. Cells 
were transfected with the empty vector (black bars) or AP-1 vector 
(open bars) or the AP-1 vector with 0.125 μg A-Fos (diagonally 
hatched bars) or 0.25 μg A-Fos (horizontally hatched bars), 
followed by 24 h treatment with 0-2.5 μM thimerosal (TM), or the 
positive control, TPA (100 nM). Luciferase activity was measured, 
normalized to protein, and reported as fold change in comparison
to control. * P< 0.05 vs. Empty Vectors,† P<0.05 vs. AP-1 Reporter 
Construct, n=3.
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Figure 4.15. Thimerosal treatment increases AP-1 
transcriptional activation through cJun. Cells were transfected
with the empty vector (black bars) or AP-1 vector (open bars) or the 
AP-1 vector with 0.25 μg TAM67 (diagonally hatched bars) or 0.5
μg TAM67 (horizontally hatched bars), followed by 24 h treatment 
with 0-2.5 μM thimerosal (TM), or the positive control, TPA (100
nM). Luciferase activity was measured, normalized to protein, and 
reported as fold change in comparison to control.  * P< 0.05 vs.
Empty Vectors,† P<0.05 vs. AP-1 Reporter Construct, n=4.
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4.16 Pretreatment with JNK inhibitor II (SP600125) Blocks Increases in Bim and 
Other Apoptotic Proteins 
 
To confirm that JNK is an essential component of this thimerosal-induced 
mitochondrial-mediated apoptotic pathway, we chose to use the cell-permeable 
JNK inhibitor II (SP600125).  By blocking the activation of JNK and its subsequent 
ability to activate transcription factors and other cellular proteins, we can determine 
if it is playing a role in thimerosal-mediated apoptosis.  SK-N-SH cells were 
pretreated for 2 h with 10 μM SP600125 followed by 2.5 μM thimerosal for 24 h, as 
above, and then examined with Western blotting.  Cells pretreated with the 
inhibitor followed by thimerosal administration showed less of an increase in levels 
of Bim (Figure 4.16A), cleaved caspase 9 (Figure 4.16B), cleaved caspase 3 
(Figure 4.16C), and cleaved PARP (Figure 4.16D), than did cells treated with 
thimerosal alone, indicating that blockage of the JNK pathway has a protective 
effect on the cells.  To confirm this, cells were examined microscopically for 
morphological changes.  The SP600125-pretreated cells showed morphology 
similar to control cells, while those treated with thimerosal alone showed 
morphological changes evident of toxicity as previously described (Humphrey et 
al., 2005; Figure 4.17). 
4.17 Blockage of cJun Transcriptional Activity Does Not Prevent Apoptosis 
 
After we established that JNK was essential to thimerosal-induced neuronal 
apoptosis, we investigated whether this response was also dependent on cJun 
activation.  Cells were again transfected with TAM67, and whole cell lysates were 
analyzed by Western blotting for changes in apoptotic parameters.  
Untransfected cells and those transfected with empty vectors or AP-1 luciferase 
reporter construct showed increases in caspase 3 cleavage when treated with  
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Figure 4.16.  JNK inhibitor II (SP600125) decreases markers of 
apoptosis. In Figures A-D Lane 1 represents SK-N-SH cells 
pretreated for 2 h with vehicle followed by 24 h treatment with 2.5 
μM thiosalicylate (Ct w/o inh).  Lane 2 represents cells pretreated 
for 2 h with 10 μM SP600125 followed by 24 h treatment with 2.5 
μM thiosalicylate (Ct w/ inh).  Lane 3 represents cells pretreated for 
2 h with vehicle followed by 24 h treatment with 2.5 μM thimerosal
(2.5 μM w/o inh).  Lane 4 represents cells pretreated with 10 μM 
SP600125 followed by 24 h treatment with 2.5 μM thimerosal (2.5 
μM w/ inh).  Western blotting was performed on whole cell lysates
to assess changes in levels of Bim (A), cleaved caspase 9 (B), 
cleaved caspase 3 (C), and cleaved PARP (D).  50 μg of whole cell
lysates loaded per lane.  GAPDH was used as a loading control.
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A B
C D
Figure 4.17.  SP600125 has a protective effect following 
thimerosal treatment. Cells were pretreated for 2 h without (A, C) 
or with (B, D) SP600125 and treated with 2.5 μM thiosalicylate (A, 
B) or 2.5 μM thimerosal (C, D), and then observed microscopically 
for morphological changes. Arrows indicate cells displaying toxicity.  
Cells were observed with a Nikon Diaphot (Frank E. Fryer Co., 
Cincinnati, OH) and photographed using a Nikon N2000 camera.  
Cells pretreated with SP600125 before thimerosal treatment show 
decreased toxicity in comparison to cells treated with thimerosal 
alone.   
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thimerosal in comparison to thiosalicylate (Figure 4.18A).  Cells transfected with 
TAM67 still underwent apoptosis when treated with 2.5 μM thimerosal, as seen 
by similar increases in cleaved caspase 9 (Figure 4.18B), cleaved PARP (Figure 
4.18C), and Bim (Figure 4.18D).  These results indicate that cJun activation is 
not an essential component of apoptosis in response to thimerosal exposure.     
 
4.18 JNK Inhibitor II (SP600125) Decreases Heme Oxygenase-1 (HO-1) Levels 
 
            Previous studies in our lab have shown that SK-N-SH cells mount a stress 
response following thimerosal treatment.  One indicator of this stress response is 
an increase in HO-1 (Marcelo et al., 2006).  To determine if this stress response is 
influenced by the thimerosal-induced activation of the JNK pathway, we used the 
SP600125 JNK inhibitor, as above.  SK-N-SH cells were pretreated for 2 h with 10 
μM SP600125 followed by 2.5 μM thimerosal for 24 h, as above, and then 
examined with Western blotting.  Cells pretreated with the inhibitor followed by 
thimerosal administration showed less of an increase in levels of HO-1 than did 
cells treated with thimerosal alone, indicating that blockage of the JNK pathway 
decreases the stress response (Figure 4.19).  This decrease in HO-1 may be due 
to the blockage of the apoptotic pathway by SP600125, thus decreasing the need 
for a stress response, or directly through the blockage of JNK activation, which 
could in turn block activation of transcription factors responsible for HO-1 gene 
transcription.   
4.19 Blockage of cJun Transcriptional Activity Does Not Affect HO-1 Levels 
 
Because the AP-1 pathway was not a component of thimerosal-induced 
apoptosis, we next wanted to determine if the stress response was mediated 
through AP-1 transcriptional activation.  Cells were again transfected with 
TAM67, and whole cell lysates were analyzed by Western blotting for changes in  
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Figure 4.18. TAM67 is not protective following thimerosal 
treatment. Untransfected cells (Untransfected; except for Bim blot) 
and those transfected with empty vectors (Empty Vectors) or AP-1 
construct (AP-1) or AP-1 construct and 0.5 μg TAM67 (TAM67) 
were treated with 2.5 μM thiosalicylate (TS) or 2.5 μM thimerosal
(TM).  Whole cell lysates were analyzed by Western blotting for
caspase 3 cleavage (A), caspase 9 cleavage (B), PARP (C), or Bim
(D).  GAPDH was used as a loading control.  50 μg protein loaded 
per lane in A and B.  15 μg protein loaded per lane in C.  20 μg 
protein loaded per lane in D.  
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Figure 4.19.  Blocking JNK activation decreases HO-1 levels. 
Lane 1 represents SK-N-SH cells pretreated for 2 h with vehicle 
followed by 24 h treatment with 2.5 μM thiosalicylate (Ct w/o inh).  
Lane 2 represents cells pretreated for 2 h with 10 μM SP600125 
followed by 24 h treatment with 2.5 μM thiosalicylate (Ct w/ inh).  
Lane 3 represents cells pretreated for 2 h with vehicle followed by 
24 h treatment with 2.5 μM thimerosal (2.5 μM w/o inh).  Lane 4 
represents cells pretreated with 10 μM SP600125 followed by 24 h 
treatment with 2.5 μM thimerosal (2.5 μM w/ inh).  Western blotting 
was performed on whole cell lysates to assess changes in levels of 
HO-1.  50 μg of whole cell lysates loaded per lane.  GAPDH was 
used as a loading control.
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apoptotic parameters.  Untransfected cells and those transfected with empty 
vectors or AP-1 construct showed increases in HO-1 when treated with 
thimerosal in comparison to thiosalicylate.  Cells transfected with TAM67 and 
treated with thimerosal showed similar changes in HO-1 levels when compared 
to the other transfected sets (Figure 4.20), indicating that the thimerosal-induced 
increases in HO-1 are not mediated through AP-1. 
 
4.20 Oxidative Stress Component is Upstream of JNK Activation 
 
Previous studies in our lab indicated that following 5 μM thimerosal 
exposure, oxidative stress increases as early as 1 hr after treatment (Marcelo et 
al., 2006).  This time point is earlier than the time point at which JNK 
phosphorylation increases (Figure 4.11).  We next wanted to determine if the 
oxidative stress component of thimerosal-induced neurotoxicity was upstream of 
the JNK activation or was part of a separate pathway.  Using the antioxidants 
Trolox (TX) and N-acetylcysteine (NAC) to decrease oxidative stress, we 
analyzed cytoplasmic fractions of thimerosal-treated cells with Western blotting to 
look at changes in phosphorylation of JNK.  Trolox is a vitamin E analog that 
works at the levels of the membrane to protect the cell from damage due to 
oxidative stress.  NAC is a precursor to glutathione, which is the most abundant 
endogenous antioxidant, and may also bind directly to sulfur-containing 
compounds, such as thimerosal, to reduce oxidative stress.  Following a 2 h 
pretreatment with TX and either 5 or 10 μM thimerosal treatment for 4 hr (Figure 
4.21A) or a 2 h pretreatment with NAC or TX and then 5 μM thimerosal treatment 
for 6 hr, phosphorylation of JNK was increased in comparison to thimerosal 
treatment alone (Figure 4.21B,C).  This increase was transient, and following 
exposure to 5 μM thimerosal for 24 h, JNK phosphorylation was decreased in 
cells pretreated with NAC or TX (Figure 4.21D,E).  At the lower concentration of 
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Figure 4.20.  TAM67 does not block HO-1 increase. Cells 
transfected with empty vectors (Empty Vectors) or AP-1 construct 
(AP-1) or AP-1 construct and 0.25 μg (TAM67-Low) or 0.5 μg
TAM67 (TAM67-High) were treated with 2.5 μM thiosalicylate (TS) 
or 2.5 μM thimerosal (TM).  Whole cell lysates were analyzed by 
Western blotting for HO-1.  GAPDH was used as a loading control. 
50 μg protein loaded per lane.
GAPDH
HO-1
Empty 
Vectors
TS      TM
TAM67
Low
TS     TM
AP-1
TS      TM
TAM67
High
TS     TM
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 2.5 μM thimerosal, pretreatment with TX also caused an increase in JNK 
phosphorylation by 6 hr and a decrease by 24 hr (Figure 4.22A,C).  NAC 
pretreatment caused a small increase in p-JNK when NAC was included with the 
treatment and no change in phosphorylation when NAC was removed, with a 
slight decrease by 24 hr (Figure 4.22B,D).  The overall decrease in JNK 
phosphorylation in cells pretreated with antioxidants prior to thimerosal treatment 
indicates that the oxidative stress component is upstream of JNK activation.  The 
transient increase in JNK phosphorylation seen at 6 hr may be due to a 
temporary stabilization of JNK in the phosphorylated state, perhaps due to an 
effect on the phosphatases that inactivate JNK.  Additionally, in some of the 
Western blots, the untreated cells and cells treated with only thiosalicylate, TX, or 
NAC alone appear to have a higher level of p-JNK than in cells treated with 
thimerosal alone, especially with the lower concentration.  On the surface this 
may seem that thimerosal actually causes a decrease in p-JNK.  However, this 
high level of basal phosphorylation is most likely due to the serum present in the 
medium used in this treatment.  The medium has to be changed when the 
pretreatments are initially added and then again when the thimerosal treatments 
are added.  In treatments where the medium is not changed and thimerosal is 
added, p-JNK is increased over control at the same time point (Figure 4.11).  
Therefore, this most likely represents a differential phosphorylation in response 
to two different stimuli.  
 
4.21 Antioxidants Affect Bim Levels 
 
We further investigated the effect of antioxidants Trolox and N-
acetylcysteine on Bim levels after a 2 hr pretreatment and 24 hr thimerosal 
treatment.  Cells pretreated with NAC or TX followed by 2.5 or 5 μM thimerosal 
and whole cell lysates were analyzed for Bim by Western blotting.  NAC and TX 
pretreatment decreased levels of Bim following 5 μM thimerosal treatment, and 
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NAC decreased Bim following 2.5 μM thimerosal treatment as well (Figure 
4.23A,B).  However, Bim levels increased with a TX pretreatment and 2.5 μM 
thimerosal treatment (Figure 4.23B).  This unexpected increase may be transient, 
as was the increase in JNK phosphorylation.  Lower concentrations of thimerosal   
take longer to have effects similar to higher concentrations, as was demonstrated 
with the MTT and LDH results (Figures 4.2, 4.3).  Therefore, further studies could 
determine if Bim levels decrease at later time points.   
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Figure 4.21.  Antioxidant pretreatment affects p-JNK levels 
following 5 μM and 10 μM thimerosal treatment.  (A) Cells were 
pretreated with vehicle or 1 mM Trolox (TX) for 2 h and then treated 
with either 10 μM thiosalicylate (Ct) or 5 or 10 μM thimerosal
without (5,10) or with TX (5/TX, 10/TX) for 4 h.  (B) Cells were
pretreated as in A and treated with 5 μM thimerosal without (5) or 
with TX (5/TX).  (C) Cells were pretreated with 1 mM NAC 
(dissolved in medium) for 2 h and then NAC was removed.  Cells 
were then treated with 5 μM thiosalicylate (Ct), NAC alone (+N), 
NAC pretreatment only (-N), 5 μM thimerosal (5), 5 μM thimerosal
with NAC (5+N), or 5 μM thimerosal with NAC pretreatment only (5-
N) for 6 hr.  (D) Same treatment as B for 24 h, and a set with no 
treatment (None).  (E) Same treatment as C for 24 h, and a set with 
no treatment (None).  50 μg protein loaded each lane, except C, 
which has 30 μg protein loaded per lane.  GAPDH was used as a 
loading control.  
E None   Ct     +N     -N      5     5+N  5-N
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D None     Ct       TX       5      5/TX
54 kDa
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p-JNK
24 h
GAPDH
GAPDH
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Figure 4.22. Antioxidant pretreatment affects p-JNK levels 
following 2.5 μM thimerosal treatment. (A) Cells were pretreated 
pretreated with vehicle or 1 mM Trolox (TX) for 2 h and treated with 
2.5 μM thimerosal without (2.5) or with TX (2.5/TX).  (B) Cells were 
pretreated with 1 mM NAC (dissolved in medium) for 2 h and then 
NAC was removed.  Cells were then treated with 2.5 μM
thiosalicylate (Ct), NAC alone (+N), NAC pretreatment only (-N), 
2.5 μM thimerosal (2.5), 2.5 μM thimerosal with NAC (2.5+N), or 
2.5 μM thimerosal with NAC pretreatment only (2.5-N) for 6 hr.  (C) 
Same treatment as A for 24 h, and a set with no treatment (None).  
(D) Same treatment as B for 24 h, and a set with no treatment 
(None).  50 μg protein loaded per lane. GAPDH was used as a 
loading control.
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Figure 4.23.  Antioxidant pretreatment affects Bim levels 
following thimerosal treatment. (A) Cells were pretreated with 
vehicle (ethanol) or 1 mM Trolox (TX) for 2 h and then treated with 
either 5 μM thiosalicylate (Ct) or 2.5 or 5 μM thimerosal without 
(2.5,5) or with TX (2.5/TX, 5/TX) for 24 h. (B) Cells were pretreated 
with 1 mM NAC (dissolved in medium) for 2 h and then NAC was 
removed.  Cells were then treated with 5 μM thiosalicylate (Ct), 
NAC alone (+N), NAC pretreatment only (-N), 2.5 or 5 μM
thimerosal (2.5, 5), 2.5 or 5 μM thimerosal with NAC (2.5+N, 5+N), 
or 5 μM thimerosal with NAC pretreatment only (5-N) for 24 hr.  25 
(A) or 50 μg (B) protein loaded per lane.
Ct       +N       -N 2.5   2.5+N  2.5-N     5      5+N    5-N
Ct       TX        2.5    2.5/TX      5        5/TX
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CHAPTER V 
 
Discussion 
 
5.1 Introduction 
 
In the present study, the SK-N-SH cell line is used as a model for 
neurotoxicity to represent the immature nervous system.  A neuronal model with 
the ability to differentiate is more suitable to this study than one of terminal 
differentiation because one of the primary concerns with mercury exposure is the 
possible effects on the developing nervous systems of fetuses, neonates, and 
infants.  This is particularly true with regard to the study of thimerosal, since 
thimerosal-containing products are administered to neonates, infants, and 
pregnant women around the world.  In addition, neuroblastoma models have 
been reported to be sensitive to mercurial toxicity (Sager and Syversen, 1984; 
Stoiber et al., 2004; Toimela and Tahti, 2004).   
 Since limited studies have been conducted to test actual mercury levels in 
infants immediately following administration of thimerosal-containing vaccines, in 
our initial studies, we used a range of concentrations for short and long time 
periods to conduct these mechanistic studies in our model.  Subsequent 
experiments used lower concentrations (1 and 2.5 μM) of thimerosal for longer 
time periods in order to more easily establish events occurring following 
treatment.  According to Magos (2001), symptoms of toxicity occur in patients 
having blood mercury levels that reach 1 μg/mL or more, which correlates to a 
concentration of 5 μM thimerosal.  Since limited studies have been conducted to 
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test actual mercury levels in infants immediately following administration of 
thimerosal-containing vaccines, we used a range of concentrations to conduct 
these mechanistic studies in our model. 
At the cellular level, mercurials readily react with sulfhydryl groups, making 
enzymes and structural proteins likely targets.  Disruption of these components 
can lead to cell death.  Monnet-Tschudi (1998) demonstrated that mercuric 
chloride causes apoptotic cell death in cultured astrocytes.  Kunimoto (1994) 
showed that primary cultures of rat cerebellar neurons undergo apoptosis when 
exposed to low concentrations of methylmercury, but undergo necrotic cell death 
when exposed to higher concentrations.  Additionally, several studies have 
shown that once organic mercurials enter the body, they can be converted to 
inorganic mercury, which has a much longer half-life than the parent compound 
(Friberg and Mottet, 1989; Norseth and Clarkson, 1970; Suda et al., 1991).  
Several studies have indicated that both inorganic and organic mercurials induce 
apoptosis in vitro as well as in vivo (Guo et al., 1998; Shenker et al., 1999, 2000).   
At the organ level, one of the primary targets for mercurials is the brain.  
Studies using Wistar rats exposed to methylmercury demonstrated that 
cerebellar granule cells underwent apoptotic cell death (Nagashima et al., 1996).  
With thimerosal treatment, Baskin et al., (2003) demonstrated changes in 
membrane permeability, DNA damage, and caspase 3 activation in both cultured 
human cerebral cortical neurons and fibroblasts.  As much as 30 years ago, 
researchers showed that mercury accumulated in rabbit brain tissue following the 
application of thimerosal-containing ophthalmic medications (Gassett et al., 
1975) and that inorganic mercury accumulated in monkey brain tissue following 
daily administration of thimerosal (Blair et al., 1975).  More recently, studies have 
shown that mercury accumulated in the brain tissue of neonatal mice given 
intramuscular injections of thimerosal, and the levels did not decrease by 7 days 
(Harry et al., 2004).  Further, Hornig et al., (2004) used an autoimmune disease-
sensitive mouse model (SJL/J) to show that some populations may have a 
genetic predisposition for sensitivity to thimerosal-induced neurotoxicity.  Similar 
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studies have found that specific MHC haplotypes may be associated with 
sensitivity to thimerosal toxicity (Havarinasab, 2004, 2005).  However, specific 
signaling pathways in thimerosal-induced neurotoxicity have not been 
established in animal models and are only beginning to be identified in tissue 
culture models.   
 
5.2 Toxicity Studies 
 
Initial studies demonstrated that SK-N-SH cells exposed to thimerosal 
underwent changes consistent with toxicity.  The MTT results indicate that with 
increasing time and concentrations of thimerosal, mitochondrial viability is 
decreased, which can lead to cell death.  Additionally, LDH release occurred, 
which is also indicative of cell death.  As cell membrane integrity is lost, in either 
necrosis or late apoptosis, LDH is released into the media surrounding the cells 
(Loo and Rillema 1998).  Morphological changes observed in SK-N-SH cells 
exposed to thimerosal included membrane blebbing, cell shrinkage, and 
detachment from the plate, which are consistent with apoptosis.  Fluorescent 
studies confirmed that cells were undergoing apoptosis.  Through use of a 
membrane-permeable stain (Hoescht 33342) and a counterstain that was 
membrane-impermeable (ethidium bromide), studies showed that nuclei were 
condensed and fragmented.  This condensation and fragmentation occurred while 
the cellular membrane was still intact, which is characteristic of apoptosis (Lincz, 
1998).  Thimerosal-induced toxicity in the SK-N-SH cell line occurred at 
concentrations similar to those used in studies with other cell lines (James et al., 
2005; Parran et al., 2005; Makani et al., 2002; Baskin et al., 2003; Yel et al., 2005).   
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5.3 Apoptosis Studies 
 
Our studies have indicated that following exposure to thimerosal, SK-N-
SH cells undergo apoptotic cell death.  Morphological studies demonstrated that 
cells shrink and display membrane blebbing (Figure 4.1), which are characteristic 
of apoptosis (Lincz, 1998).  Additional studies using fluorescent microscopy 
indicated that nuclear condensation and fragmentation were occurring while the 
cellular membrane was still intact (Figure 4.4), which is also characteristic of 
apoptosis (Lincz, 1998).  Makani et al., (2002) showed apoptosis in Jurkat T cells 
exposed to similar concentrations of thimerosal as used in our study.  Several 
studies have confirmed these findings in neuroblastoma cell lines similar to the 
model used in the present study (Baskin et al., 2003; Parran et al., 2005; Yel et 
al., 2005).   
Apoptosis occurs through two main pathways:  intrinsic pathway and 
extrinsic pathway, and studies in our lab have indicated that thimerosal-induced 
neurotoxicity occurs through a mitochondrial-mediated pathway (Humphrey et al., 
2005).  This intrinsic pathway is characterized by release of cytochrome c from 
the mitochondria (Figure 4.6).  Mitochondrial membrane changes due to factors 
such as calcium alterations or oxidative stress can lead to release of cytochrome 
c from the mitochondria.  Both of these events have been shown to occur 
following thimerosal treatment (Ueha-Ishibashi et al., 2004a, 2004b, 2005; James 
et al., 2005, Yel et al., 2005, Marcelo et al., 2006).  Cytochrome c release is 
followed by cleavage of caspase 9 (Figure 4.7), which then cleaves caspase 3 
(Figure 4.8).    
Our studies were the first to show that thimerosal-induced apoptosis is 
mediated specifically through caspase 9, not caspase 8 (Humphrey et al., 2005).  
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This observation was later confirmed in another neuroblastoma cell line by Yel et 
al. (2005).  Active caspase 3 then proceeds to cleave substrates that perpetuate 
the apoptotic response.  One such substrate is PARP.  PARP is involved in 
sensing DNA damage, and degradation of PARP by caspase 3 is another marker 
of apoptosis (Figure 4.10).  By contrast, the activation of PARP can lead to 
necrosis through the depletion of NAD+, which leads to inactivation of ion 
channels followed by cell swelling (Scovassi and Diederich, 2004; Diefenbach 
and Burkle, 2005).  Yel et al. (2005) also found that thimerosal leads to cleavage 
of PARP.  All our results, coupled with confirmatory results found by other 
laboratories, indicate that thimerosal induces apoptosis through a mitochondrial-
mediated pathway.  However, further investigation led to more information 
concerning the signaling pathways activated by thimerosal.   
 
5.4 JNK/AP-1 Studies 
 
Studies have shown that JNK activation is essential to neuronal apoptosis 
(Davis, 2000; Karin and Gallagher 2005; Kim et al., 2005b; Kuan et al., 1999; Lei 
and Davis 2003; Okuno et al., 2004; Yang et al., 1997).  Additionally, reports have 
shown that AP-1 activation and increases in cJun and cFos can be involved in 
neuronal apoptosis (Sastry and Rao, 2000).  Our studies have shown that 
thimerosal induces increases in phosphorylation of JNK and cJun, as well as 
increases in levels of cJun and cFos.  Thimerosal also induced AP-1 
transcriptional activity with the involvement of cJun, but not cFos.  In determining 
which components were essential to apoptosis, we found that JNK, but not cJun, 
was necessary for thimerosal-induced apoptosis in SK-N-SH cells.  Studies with 
the TAM67 dominant negative show that when cJun is unable to activate 
transcription, SK-N-SH cells treated with thimerosal still undergo apoptosis, as 
shown by activation of caspase 9 and 3, and degradation of PARP.  These results 
suggest that cJun activation is not required for thimerosal-induced cell death.  
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Therefore, the AP-1 transcription factor must have another role following this 
environmental insult.   
Following cellular damage, cells enter into a period of cell cycle arrest in 
order to repair damage.  Shaulian et al. (2000) found that induction of cJun is 
required for re-entry into the cell cycle following UV damage.  In the case of 
thimerosal exposure, we saw increases in levels of cJun, which can be increased 
in response to AP-1 activation, occurring at a later time point than JNK and cJun 
activation. This protein increase could be the result of an attempt by the cell to 
prepare to re-enter the cell cycle following repair.  cJun can stimulate re-entry into 
the cell cycle through induction of cyclin D1, which drives cell proliferation, or 
through repression of p21Cip1, which promotes p53 activity (Shaulian et al., 2000).  
On the other hand, Shaulian and Karin (2002) suggest that the role of cJun in 
apoptosis and survival might be more of a balancing act between cJun-mediated 
induction of proapoptotic and antiapoptotic target genes, including FasL, Bcl3, and 
Bim.  Depending on cell type, the nature of the stress, duration of exposure, and 
other active transcription factors, the balance may shift toward either survival or 
apoptosis.  Further studies will be needed to determine if either of these events is 
occurring in response to thimerosal, since SK-N-SH cells treated with the mercury-
containing compound appear unable to successfully process the toxic insult, and 
thus proceed down an apoptotic pathway.  Additionally, studies have shown that 
the requirement for c-Jun phosphorylation in JNK-mediated apoptosis is 
dependent on the stress signal and the cell type  (Yang et al., 1997; Behrens et al., 
1999; Hochedlinger et al., 2002).  Additionally, Besirli and Johnson (2003) report 
that c-Jun phosphorylation may be independent of JNK activation in DNA damage-
induced apoptosis.  However, in our studies we found that SP600125 was able to 
block c-Jun phosphorylation (Figure 3.4), indicating that c-Jun phosphorylation was 
JNK-mediated in response to thimerosal. 
Our studies are the first to show that proapoptotic Bim levels are increased 
in response to thimerosal treatment, and are decreased when cells were 
pretreated with SP600125 but not when transfected with TAM67, indicating that 
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perhaps JNK and Bim are interacting directly.  JNK has been shown to activate 
Bim through phosphorylation, allowing Bim to contribute to apoptosis by interaction 
with other Bcl2 proteins (Becker et al., 2004; Harris and Johnson, 2001).  Under 
normal conditions, Bim is attached to LC8 in the dynein motor complex, but 
translocates to the mitochondrial membrane when activated, wherein Bim interacts 
with Bax/Bad, causing pore formation and cytochrome c release, ultimately leading 
to apoptosis (Mollinedo and Gajate, 2003).  According to Putcha et al. (2001) this 
Bim-mediated apoptosis is specific to neuronal cells, and does not occur in 
nonneuronal cells in the brain.  Previous studies in our lab have shown that 
thimerosal-treated SK-N-SH neuroblastoma cells have increases in cytochrome c 
release, so this interaction with Bim is a potential mechanism by which JNK could 
be directly causing apoptosis in these cells.  Additionally, Bim is an AP-1 target 
gene, but after blocking AP-1 transcription, we still see increases in levels of Bim, 
indicating that in SK-N-SH cells Bim levels may be increased in response to other 
transcription factors, such as members of the Forkhead family (Gilley et al., 2003; 
Sunters et al., 2003).  Essers et al. (2004) found that JNK can phosphorylate 
Forkhead transcription factors, leading to apoptotic cell death.  Further studies will 
need to be conducted to determine both the significance of the AP-1 activation and 
the substrates through which JNK is mediating intrinsic apoptotic cell death, 
including the investigation of the JNK/Bim interaction.    
 
5.5 JNK/Oxidative Stress Studies 
 
We have shown in our laboratory that thimerosal induces oxidative stress 
in the SK-N-SH neuroblastoma cell line (Marcelo et al., 2006).  Other studies 
have also found that thimerosal induces oxidative stress (Kim et al., 2002; Baskin 
et al., 2003; James et al., 2005; Yel et al., 2005).  Baskin et al. (2003) suggest 
that free radicals may be involved in thimerosal-induced damage to the cell 
membrane.  Inorganic and organic mercurials, including thimerosal, have been 
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shown to increase ROS and induce a state of “oxidative stress” in numerous cell 
types; however, it is unknown whether this is a direct effect of the metal.  Studies 
have shown that thimerosal causes release of calcium from intracellular stores 
followed by an influx of extracellular calcium (Gericke et al., 1993; Elferink, 
1999), which can lead to an increase in ROS and RNS production in the 
mitochondria.  Both ROS and RNS have been shown to cause apoptotic cell 
death (McGowan et al., 1996; Szabo, 1996; Cai and Jones, 1998; Chung et al., 
2001).  The ROS/RNS can directly interact with macromolecules such as 
proteins and nucleic acids, leading to perturbations of vital cellular functions, 
which may result in cell death.   
Our studies have shown that thimerosal-induced apoptosis is JNK-
dependent.  We have also shown that antioxidants could attenuate thimerosal-
induced apoptosis (Marcelo et al., 2006).  Apoptosis involving the JNK signaling 
pathway has been shown to be redox-sensitive, so our goal was to determine if 
the oxidative stress component of thimerosal-induced apoptosis was upstream of 
JNK or part of a separate pathway.  Through the use of antioxidants, we found 
that both TX and NAC cause a transient increase in p-JNK in comparison to 
thimerosal alone.  By 24 h the antioxidant pretreatment led to a decrease in p-
JNK in comparison to thimerosal alone.  Many studies have shown that oxidative 
stress can act upstream of JNK (Bruckner et al., 2003; Soh et al., 2000; Choi et 
al., 1999; Garcia-Fernandez et al., 2002; Kamata et al., 2005).   
Choi et al. 1999 reported that they were able to attenuate the oxidative 
stress-induced JNK activation through the use of NAC.  In our studies we found 
that both TX and NAC decrease JNK activation as well.  However, we found that 
antioxidant pretreatment caused p-JNK levels to rise following thimerosal 
treatment before they ultimately were decreased over time.  Most studies with 
JNK and antioxidants indicate that reducing the oxidative stress subsequently 
reduces the JNK activation.  Studies have shown that this decrease could be due 
to the inhibition of MAPK phosphatases (Kamata et al., 2005).  On the contrary, 
few studies have found that antioxidants cause increases in p-JNK.  Studies with 
93 
the green tea antioxidant (-)-epigallocatechin-3-gallate (EGCG) have shown that 
EGCG can activate the JNK pathway (Chen et al., 2000; Kim et al., 2005a).  
However, Kim et al. (2005) found that oxidative stress actually increases 
following EGCG administration, so it must be altering redox status without having 
an antioxidant effect.  The mechanism remains to be discovered.  Additionally, 
the EGCG effect may be cell line specific, as Balasubramanian et al. (2002) 
found that EGCG acts through p38, not JNK or ERK, in human keratinocytes.  
 From these pieces of information, we could speculate that in the process 
of attenuating thimerosal-induced neurotoxicity through the use of antioxidants, 
the initial altering of the redox status has the short-lived effect of increasing JNK 
activation before eventually decreasing levels of p-JNK, and this effect could be a 
stabilizing effect on p-JNK, perhaps through effects on MAPK phosphatases or 
possibly through an overall stabilizing effect on the cell, such as when it enters 
cell cycle arrest to repair thimerosal-induced damage.  Finally, this effect could 
be a differential phosphorylation of JNK; by reducing the apoptotic response with 
antioxidants, the cell could be responding to other factors, such as the serum in 
the medium.   
 
5.6 Summary 
 
We have shown that thimerosal can cause mitochondrial-mediated 
apoptosis in a human neuroblastoma cell line.  To our knowledge, this is the first 
study to chronologically show the mitochondrial, cytosolic and nuclear events 
associated with thimerosal-mediated toxicity in a non-differentiated neuronal 
system.  Our study is the first demonstration that thimerosal can induce activation 
of JNK and AP-1 in the SK-N-SH neuroblastoma cell line.  We showed that 
activation of cJun and AP-1 transcriptional activity following thimerosal treatment 
does not appear to be involved in the induction of apoptosis, as demonstrated with 
the studies using the cJun dominant negative.  Furthermore, we were able to show 
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that JNK is an essential upstream component of this pathway through use of the 
JNK inhibitor SP600125.  This compound was able to attenuate activation of 
downstream components of mitochondrial-mediated cell death and subsequently 
protect the cells from apoptosis.  We were also able to use antioxidants to show 
that the JNK signaling pathway is redox sensitive, with the oxidative stress 
component upstream of JNK.  The pathway determined by our studies is 
presented in Figure 5.1, and Figure 5.2 displays a time line for events following 5 
μM thimerosal treatment of SK-N-SH cells.  These results are significant because 
identifying specific signaling pathways activated in response to thimerosal 
exposure presents pharmacological targets for attenuating potential toxicity in 
patients exposed to thimerosal-containing products.   
 
5.7 Future Studies 
 
Many questions remain to be answered concerning the mechanism of 
thimerosal-induced neurotoxicity.  A concern that has arisen due to the presence 
of thimerosal in vaccine is whether low levels of thimerosal are safe, and at what 
concentration should patients be concerned.  Our studies use a range of 
concentrations, but more studies could be undertaken with the concentrations at 
the lowest range (nanomolar or lower) and for longer periods of time to assess the 
toxic effects.  It is important to see if very low concentrations have similar effects 
over time, leading ultimately to the same toxic effects seen in our studies, or if 
another biological response dominates, such as an effective survival response.  
This information is important because effects seen with lower thimerosal 
exposures could be different than with higher exposures.  Additionally, the 
estimated 7-day half-life of ethylmercury leads to a lengthy exposure before the 
compound is considered cleared from the body (approximately 28 days).  It will be 
important to learn if cells can repair damage following exposure to lower levels of 
thimerosal, since we have demonstrated that a stress response is mounted by the 
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SK-N-SH cells after treatment.  Investigating survival signaling following thimerosal 
treatment, along with the effects of these lower concentrations over time, could 
lead to more information concerning the potential toxic effects of thimerosal in 
vaccines.   
Further investigation into the upstream and downstream components of the 
JNK signaling pathway could also yield beneficial information concerning 
thimerosal toxicity by providing more targets for development of drugs to attenuate 
or alleviate the potential toxic effects.  Components upstream of JNK have not 
been elucidated in relation to thimerosal-induced neurotoxicity.   MAPKKK (ASK1) 
and MAPKK (MKK4/7) are important starting points, but other candidates for 
activation of JNK signaling may by the small GTPases.  Additionally, it will be 
necessary to determine if any of these are signaling intermediaries between 
thimerosal-induced oxidative stress and JNK signaling, and if they are not, then 
are some other molecules, such as H2O2 or 4HNE, acting to activate JNK.   
Downstream components of the pathway may also be targets for reducing toxicity.  
These targets may include transcription factors other than AP-1, such as Forkhead 
transcription factors, or gene that JNK signaling may be targeting.  Microarray 
studies using SP600125 in conjunction with thimerosal treatment may provide 
important clues to JNK-mediated gene alterations.  These potential genetic 
changes may also lead to information concerning other signaling pathways that 
may be interacting with the JNK pathway following thimerosal treatment.  Signaling 
pathways are not isolated, with cross-talk between pathways occurring regularly.  
Investigation into other signaling pathways that are interacting with JNK, and 
information about regulation of those pathways may provide additional targets for 
reducing potential toxic effects of thimerosal.   
Gathering this mechanistic information from cell line such as the SK-N-SH 
neuroblastoma cell line provides a springboard to study thimerosal-induced 
neurotoxicity in an animal model.  Animal studies using thimerosal are few, and 
many concentration solely on the immune system and not on toxicity.  However, 
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moving these studies into an animal model is an important step in clarifying what is 
happening in humans exposed to thimerosal.   The studies conducted with 
autoimmune-sensitive mice have given toxicologists a model to use in studying 
thimerosal-induced neurotoxicity.  Using a model that is known to be sensitive to 
thimerosal, studies can be undertaken that determine if effects seen in the SK-N-
SH cell line are occurring in vivo.  Studies could investigate if oxidative stress is 
increased, if JNK signaling is activated, if apoptosis is occurring, and if it is 
mediated by the same mechanism as in the cell line.  Answering these questions 
would provide a wealth of information that could be used to study mechanisms by 
which neurotoxicity could be alleviated in patients exposed to thimerosal. 
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Figure 5.1.  Proposed Pathway of Thimerosal-Induced 
Neurotoxicity. 
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Figure 5.2.  Time line for events following 5 μM thimerosal 
treatment of SK-N-SH cells. 
5 μM Thimerosal
Caspase 9 cleavage-8 h
Cytochrome c release-6 h
JNK, cJun activation-2 h
Oxidative stress-1 h
Caspase 3 cleavage/activity-6-24 h
Bim, cJun, cFos levels-24 h
PARP degradation, LDH release,             
DNA fragmentation and condensation-24 h
Apoptosis-24 h
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